ehc-20220201
false000078516100007851612022-02-012022-02-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 1, 2022
Encompass Health Corporation
(Exact name of Registrant as specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-1031563-0860407
(Commission File Number)(IRS Employer Identification No.)
9001 Liberty Parkway, Birmingham, Alabama 35242
(Address of Principal Executive Offices, Including Zip Code)
(205) 967-7116
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.     Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareEHCNew York Stock Exchange


The information contained herein is being furnished pursuant to Item 2.02 of Form 8‑K, “Results of Operations and Financial Condition,” and Item 7.01 of Form 8-K, “Regulation FD Disclosure.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 2.02. Results of Operations and Financial Condition.
    On February 1, 2022, Encompass Health Corporation (“Encompass Health” or the “Company”) issued a press release reporting the financial results of the Company for the three months and year ended December 31, 2021. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.
    The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on hospitals and home health and hospice locations open throughout both the full current and prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.
ITEM 7.01. Regulation FD Disclosure.
See Item 2.02, “Results of Operations and Financial Condition,” above.
In addition, a copy of the supplemental information which will be discussed during the Company’s earnings call at 10:00 a.m. Eastern Time on Wednesday, February 2, 2022 is attached to this report as Exhibit 99.2 and incorporated herein by reference.
Note Regarding Presentation of Non-GAAP Financial Measures
The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow.
The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”). The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging and equity instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company’s ongoing operating performance. Accordingly, they can complicate comparisons of the Company’s results of operations across periods and comparisons of the Company’s results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States (“GAAP”) as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. The Company reconciles adjusted earnings per share to earnings per share in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.
The leverage ratio referenced therein is defined as the ratio of consolidated total debt to Adjusted EBITDA for the trailing four quarters. The Company believes its leverage ratio and Adjusted EBITDA are measures of its ability to service its debt and its ability to make capital expenditures. Additionally, the leverage ratio is a standard measurement used by investors to gauge the creditworthiness of an institution. The Company’s credit agreement also includes a maximum leverage ratio financial covenant which allows the Company to deduct up to $300 million of cash on hand from consolidated total debt. The Company reconciles Adjusted EBITDA to net income and to net cash provided by operating activities in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. Adjusted EBITDA for the Company’s reportable segments is reconciled to net income from continuing operations before income tax expense in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.


The Company uses Adjusted EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company’s credit agreement, which is discussed in more detail in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Liquidity and Capital Resources,” and Note 10, Long-term Debt, to the consolidated financial statements included in its Annual Report on Form 10‑K for the year ended December 31, 2021 (the “2021 Form 10‑K”), when filed. These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under the credit agreement—its interest coverage ratio and its leverage ratio—could result in the Company’s lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might be on terms less favorable to those in the Company’s existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the Company’s assessment of its liquidity.
In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as “Adjusted Consolidated EBITDA,” allows the Company to add back to consolidated net income interest expense, income taxes, and depreciation and amortization and then add back to consolidated net income (1) all unusual or nonrecurring items reducing consolidated net income (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3) non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4) share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment debt and acquisitions, and (7) any restructuring charges not in excess of 20% of Adjusted Consolidated EBITDA. The Company also subtracts from consolidated net income all unusual or nonrecurring items to the extent they increase consolidated net income.
The calculation of Adjusted EBITDA under the credit agreement does not require us to deduct net income attributable to noncontrolling interests or gains on fair value adjustments of hedging and equity instruments, disposal of assets and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement’s “unusual or nonrecurring” classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, the Company’s ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.
Adjusted EBITDA is not a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2021 Form 10-K, when filed.
The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company’s capacity to reduce debt, pursue development activities, and return capital to its common stockholders. The calculation of adjusted free cash flow and a reconciliation of net cash provided by operating activities to adjusted free cash flow are included in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. The Company’s definition of adjusted free cash flow is limited and does not represent residual cash flows available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2021 Form 10‑K, when filed, and in the press release attached as Exhibit 99.1 for the GAAP measures of cash flows from operating, investing, and financing activities.


Forward-Looking Statements
The information contained in the press release and supplemental information includes certain estimates, projections, and other forward-looking statements that involve known and unknown risks and relate to, among other things, future events, including the timing and effects, such as the tax-free treatment and the incremental costs, of the spin off and rebranding of the home health and hospice business and its impact on the business model, outlook and guidance, the expected impact of the COVID-19 pandemic on Encompass Health’s business and financial assumptions, the Company’s business strategy, financial plans, dividend strategies or payments, effective income tax rates, plans to repurchase its debt or equity securities, future financial performance, projected business results or model, ability to return value to its shareholders, projected capital expenditures, leverage ratio, acquisition opportunities, and the impact of future legislation or regulation. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “targets,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These estimates, projections, and other forward-looking statements are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.
There can be no assurance that any estimates, projections, or forward-looking statements will be realized.
All such estimates, projections, and forward-looking statements speak only as of the date hereof. The Company undertakes no duty to publicly update or revise that information.
You are cautioned not to place undue reliance on the estimates, projections, and other forward-looking statements in this report, the press release, and supplemental information as they are based on current expectations and general assumptions and are subject to various risks, uncertainties, and other factors, including those set forth in the attached press release and in the 2021 Form 10‑K, when filed, and in other documents the Company previously filed with the SEC, many of which are beyond the Company’s control. These factors may cause actual results to differ materially from the views, beliefs, and estimates expressed herein.
ITEM 9.01. Financial Statements and Exhibits.
(d)    Exhibits.
Exhibit NumberDescription
104Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
ENCOMPASS HEALTH CORPORATION
By:
/S/   DOUGLAS E. COLTHARP
Name:Douglas E. Coltharp
Title:Executive Vice President and Chief Financial Officer
Dated: February 1, 2022


Exhibit 99.1
encompasshealthnewlogoa15.jpg
Media ContactFebruary 1, 2022
Casey Winger, 205 447-6410
[email protected]
Investor Relations Contact
Mark Miller, 205 970-5860
[email protected]
Encompass Health reports results for fourth quarter 2021
and issues full-year 2022 guidance

BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), a national leader in integrated healthcare, offering facility-based and home-based patient care through its network of inpatient rehabilitation hospitals and home health and hospice agencies, today reported its results of operations for the fourth quarter and full year ended December 31, 2021.
“We delivered solid financial results in 2021, including double-digit growth in consolidated revenue and Adjusted EBITDA in spite of the challenges related to the pandemic," said President and Chief Executive Officer of Encompass Health Mark Tarr. "Our hospital and home care teams have continued to provide high quality, compassionate care to patients in need of our services. We remain confident in the long-term prospects for both of our businesses."
Consolidated results
Growth
Q4 2021Q4 2020DollarsPercent
(In Millions, Except per Share Data)
Net operating revenues$1,318.7 $1,214.4 $104.3 8.6 %
Income from continuing operations attributable to Encompass Health per diluted share
0.91 0.86 0.05 5.8 %
Adjusted earnings per share0.97 0.93 0.04 4.3 %
Cash flows provided by operating activities
123.8 279.7 (155.9)(55.7)%
Adjusted EBITDA252.7 239.9 12.8 5.3 %
Adjusted free cash flow61.7 213.0 (151.3)(71.0)%
Year Ended December 31,
20212020
Cash flows provided by operating activities
$715.8 $704.7 11.1 1.6 %
Adjusted free cash flow498.8 579.9 (81.1)(14.0)%
Revenue growth in the fourth quarter resulted from strong discharge growth and favorable pricing in our inpatient rehabilitation segment.
The increase in income from continuing operations attributable to Encompass Health per diluted share and adjusted earnings per share in 2021 primarily resulted from revenue growth.
1

Cash flows provided by operating activities grew 1.6% in 2021. Adjusted free cash flow decreased 14.0% as a result of increased working capital and cash tax payments.
See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.
Inpatient rehabilitation segment results
Growth
Q4 2021Q4 2020DollarsPercent
Net operating revenues:(In Millions)
Inpatient
$1,015.2 $914.9 $100.3 11.0 %
Outpatient and other
27.4 18.2 9.2 50.5 %
Total segment revenue
$1,042.6 $933.1 $109.5 11.7 %
(Actual Amounts)
Discharges50,977 46,503 4,474 9.6 %
Same-store discharge growth
6.0 %
Net patient revenue per discharge$19,915 $19,674 $241 1.2 %
Revenue reserves related to bad debt as a percent of revenue
2.3 %2.2 %10 basis points
(In Millions)
Adjusted EBITDA$236.3 $218.0 $18.3 8.4 %
•Revenue – Inpatient revenue growth resulted from increased volumes and pricing. Total discharge growth for the fourth quarter of 2021 was 9.6% with same-store growth of 6.0%. Revenue reserves related to bad debt as a percent of revenue increased 10 basis points, primarily attributable to a shift in payor mix.
Growth in net patient revenue per discharge of 1.2% primarily resulted from an increase in reimbursement rates, partially offset by payor mix (faster growth in Managed Care and Medicare Advantage).
The increase in outpatient and other revenue included an increase of $9.7 million in provider tax revenues (offset by an increase of approximately $4.7 million in provider tax expense included in other operating expenses).
•Adjusted EBITDA – The 8.4% increase in Adjusted EBITDA in the fourth quarter of 2021 primarily resulted from revenue growth. Higher compensation costs were partially offset by improved operating leverage in hospital operating expenses.
2

Home health and hospice segment results
Growth
Q4 2021Q4 2020DollarsPercent
Net operating revenues:(In Millions)
Home health
$224.0 $227.7 $(3.7)(1.6)%
Hospice
52.1 53.6 (1.5)(2.8)%
Total segment revenue
$276.1 $281.3 $(5.2)(1.8)%
Adjusted EBITDA$52.6 $55.5 $(2.9)(5.2)%
Home Health
Starts of care:(Actual Amounts)
Total admissions50,817 48,533 2,284 4.7 %
Same-store total admissions growth2.4 %
Total recertifications32,621 33,497 (876)(2.6)%
Total starts of care83,438 82,030 1,408 1.7 %
Episodic admissions37,908 40,830 (2,922)(7.2)%
Same-store episodic admissions growth(9.5)%
Episodic recertifications27,273 30,064 (2,791)(9.3)%
Total episodic starts of care65,181 70,894 (5,713)(8.1)%
Revenue per episode$3,010 $2,883 $127 4.4 %
Hospice
Admissions:
Same store2,861 3,348 (487)(14.5)%
New store362 — 362 10.8 %
Total admissions3,223 3,348 (125)(3.7)%
•Revenue – Home health total admissions increased 4.7% and same-store total admissions increased 2.4%.
Episodic admissions declined 7.2% in the quarter. Approximately 50% of the decline related to the conversion of admissions to non-episodic under a large managed care contract initiated in February 2021.
Home health revenue per episode increased 4.4%, driven by an increase in Medicare reimbursement and patient mix.
•Adjusted EBITDA - The 5.2% decrease in Adjusted EBITDA resulted primarily from higher costs of services related to industry-wide staffing challenges.
3

General and administrative expenses
Q4 2021% of Consolidated RevenueQ4 2020% of Consolidated Revenue
(In Millions)
General and administrative expenses, excluding stock-based compensation
$36.2 2.7%$33.6 2.8%
General and administrative expenses decreased as a percent of consolidated revenue primarily due to the increased revenue base year-over-year.
General and administrative expenses in the above table exclude $13.3 million in costs associated with the strategic alternatives review of the Company's home health and hospice business for the fourth quarter of 2021.
Full-year consolidated results
Full-YearGrowth
20212020DollarsPercent
(in millions, except per share data)
Net operating revenues$5,121.6 $4,644.4 $477.2 10.3 %
Income from continuing operations attributable to Encompass Health per diluted share
4.11 2.85 1.26 44.2 %
Adjusted earnings per share4.23 2.89 1.34 46.4 %
Adjusted EBITDA1,028.0 860.3 167.7 19.5 %
See the attached supplemental information for additional details regarding these calculations.
Announced spin off of the home health and hospice business
On January 19, 2022, the Company announced its intention to spin off its home health and hospice business to form an independent, publicly traded company (the "HH&H Business") and to rebrand the HH&H Business as Enhabit Home Health & Hospice. The spin-off, which is expected to be tax-free to Encompass Health's shareholders, will result in Encompass Health shareholders owning stock in both companies. The Company intends to consummate the spin-off in the first half of 2022, subject to various conditions, including the effectiveness of a Form 10 registration statement, regulatory approvals and receipt of a favorable IRS private letter ruling. Additional information regarding the spin-off is provided in the supplemental slides accompanying this release.
2022 guidance
The Company provided the following guidance for full-year 2022.
2022 Guidance Ranges
(In Millions, Except Per Share Data)
Net operating revenues$5,380 to $5,500
Adjusted EBITDA$1,015 to $1,065
Adjusted earnings per share from continuing operations attributable to Encompass Health
$3.83 to $4.19
The Company's 2022 guidance assumes the continuation of the current structure of the business for 2022. Guidance is not inclusive of any costs incurred in 2022 related to the preparations for the planned spin-off of Enhabit Home Health & Hospice including rebranding, professional fees, or personnel additions specifically required for an independent public company.
4

For additional considerations regarding the Company's 2022 guidance ranges, see the supplemental information posted on the Company's website at http://investor.encompasshealth.com. See also the “Other information” section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.
Earnings conference call and webcast
The Company will host an investor conference call at 10:00 a.m. Eastern Time on Wednesday, February 2, 2022 to discuss its results for the fourth quarter of 2021. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.
The conference call may be accessed by dialing 866 342-8591 and giving the pass code EHCQ421. International callers should dial 203 518-9713 and give the same pass code. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.
About Encompass Health
As a national leader in integrated healthcare services, Encompass Health (NYSE: EHC) offers both facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. With a national footprint that includes 145 hospitals and 251 home health locations and 96 hospice locations in 42 states and Puerto Rico, the Company provides high-quality, cost-effective integrated healthcare. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Other information
The information in this press release is summarized and should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”), when filed, as well as the Company's Current Report on Form 8-K filed on February 1, 2022 (the “Q4 Earnings Form 8-K”), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at http://investor.encompasshealth.com for reference during its February 2, 2022 earnings call.
The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q4 Earnings Form 8-K. Readers are encouraged to review the “Note Regarding Presentation of Non-GAAP Financial Measures” included in the Q4 Earnings Form 8-K which provides further explanation and disclosure regarding the Company’s use of these non-GAAP financial measures.
Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP.
5

However, the following reasonably estimable GAAP measures for 2022 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:
•Interest expense and amortization of debt discounts and fees - estimate of $160 million to $170 million
•Amortization of debt-related items - approximately $10 million
The Q4 Earnings Form 8-K and, when filed, the 2021 Form 10-K can be found on the Company's website at
http://investor.encompasshealth.com and the SEC's website at www.sec.gov.
6
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
For the Three Months Ended December 31,For the Year Ended December 31,
 2021202020212020
(In Millions)
Net operating revenues$1,318.7 $1,214.4 $5,121.6 $4,644.4 
Operating expenses:    
Salaries and benefits761.0 686.1 2,886.5 2,682.0 
Other operating expenses176.8 163.1 685.2 634.4 
Occupancy costs20.0 20.4 80.2 81.2 
Supplies54.2 51.7 209.3 200.5 
General and administrative expenses60.6 37.8 197.3 155.5 
Depreciation and amortization65.8 62.3 256.6 243.0 
Government, class action, and related settlements— — — 2.8 
Total operating expenses1,138.4 1,021.4 4,315.1 3,999.4 
Loss on early extinguishment of debt— 2.3 1.0 2.3 
Interest expense and amortization of debt discounts and fees40.1 46.2 164.6 184.2 
Other income(5.9)(4.2)(12.3)(10.6)
Equity in net income of nonconsolidated affiliates(1.1)(1.0)(4.0)(3.5)
Income from continuing operations before income tax expense147.2 149.7 657.2 472.6 
Provision for income tax expense31.5 38.0 139.6 103.8 
Income from continuing operations115.7 111.7 517.6 368.8 
Loss from discontinued operations, net of tax— — (0.4)— 
Net and comprehensive income115.7 111.7 517.2 368.8 
Less: Net and comprehensive income attributable to
noncontrolling interests
(24.1)(25.7)(105.0)(84.6)
Net and comprehensive income attributable to
Encompass Health
$91.6 $86.0 $412.2 $284.2 
Weighted average common shares outstanding:  
Basic99.0 98.7 99.0 98.6 
Diluted100.2 100.1 100.2 99.8 
Earnings per common share:
Basic earnings per share attributable to Encompass Health common shareholders:
   
Continuing operations
$0.92 $0.87 $4.15 $2.87 
Discontinued operations
— — — — 
Net income
$0.92 $0.87 $4.15 $2.87 
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations
$0.91 $0.86 $4.11 $2.85 
Discontinued operations
— — — — 
Net income
$0.91 $0.86 $4.11 $2.85 
Amounts attributable to Encompass Health: 
Income from continuing operations$91.6 $86.0 $412.6 $284.2 
Loss from discontinued operations, net of tax— — (0.4)— 
Net income attributable to Encompass Health$91.6 $86.0 $412.2 $284.2 
7
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
December 31, 2021December 31, 2020
 (In Millions)
Assets  
Current assets:  
Cash and cash equivalents$54.8 $224.0 
Restricted cash65.1 65.4 
Accounts receivable680.3 572.8 
Prepaid expenses and other current assets121.2 86.4 
Total current assets921.4 948.6 
Property and equipment, net2,601.6 2,206.6 
Operating lease right-of-use assets242.0 245.7 
Goodwill2,427.9 2,318.7 
Intangible assets, net417.5 431.3 
Other long-term assets254.5 295.0 
Total assets$6,864.9 $6,445.9 
Liabilities and Shareholders’ Equity
Current liabilities:  
Current portion of long-term debt$42.8 $38.3 
Current operating lease liabilities38.4 44.8 
Accounts payable137.6 115.0 
Accrued payroll265.8 253.8 
Accrued interest payable44.5 47.1 
Other current liabilities219.7 218.3 
Total current liabilities748.8 717.3 
Long-term debt, net of current portion3,243.9 3,250.6 
Long-term operating lease liabilities213.1 209.6 
Self-insured risks123.8 121.2 
Deferred income tax liabilities86.7 51.8 
Other long-term liabilities49.4 93.8 
 4,465.7 4,444.3 
Commitments and contingencies
Redeemable noncontrolling interests42.2 31.6 
Shareholders’ equity:  
Encompass Health shareholders’ equity1,911.3 1,588.0 
Noncontrolling interests445.7 382.0 
Total shareholders’ equity2,357.0 1,970.0 
Total liabilities and shareholders’ equity$6,864.9 $6,445.9 
8
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 For the Year Ended December 31,
 20212020
 (In Millions)
Cash flows from operating activities:  
Net income$517.2 $368.8 
Loss from discontinued operations, net of tax0.4 — 
Adjustments to reconcile net income to net cash provided by operating activities—
  
Provision for government, class action, and related settlements— 2.8 
Depreciation and amortization256.6 243.0 
Amortization of debt-related items7.8 7.2 
Loss on early extinguishment of debt1.0 2.3 
Equity in net income of nonconsolidated affiliates(4.0)(3.5)
Distributions from nonconsolidated affiliates2.9 3.8 
Stock-based compensation32.8 29.5 
Deferred tax expense27.8 52.4 
Other, net(8.2)5.9 
Changes in assets and liabilities, net of acquisitions —  
Accounts receivable(64.3)(38.1)
Prepaid expenses and other assets(42.0)0.1 
Accounts payable14.9 13.6 
Accrued payroll(38.1)92.0 
Other liabilities11.5 (74.9)
Net cash used in operating activities of discontinued operations(0.5)(0.2)
Total adjustments198.2 335.9 
Net cash provided by operating activities715.8 704.7 
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired(118.6)(1.1)
Purchases of property and equipment(528.9)(396.0)
Additions to capitalized software costs(15.8)(8.7)
Purchases of intangible assets(6.5)(3.5)
Proceeds from sale of restricted investments— 12.6 
Purchases of restricted investments(9.0)(8.7)
Other, net12.5 (2.1)
Net cash used in investing activities(666.3)(407.5)
(Continued)
9
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(Unaudited)
For the Year Ended December 31,
20212020
(In Millions)
Cash flows from financing activities:  
Proceeds from bond issuance— 992.5 
Principal payments on debt, including pre-payments(214.5)(718.3)
Borrowings on revolving credit facility265.0 330.0 
Payments on revolving credit facility(65.0)(375.0)
Principal payments under finance lease obligations(51.8)(22.5)
Debt amendment and issuance costs— (20.3)
Repurchases of common stock, including fees and expenses— (6.1)
Dividends paid on common stock(112.4)(111.9)
Purchase of equity interests in consolidated affiliates— (162.3)
Distributions paid to noncontrolling interests of consolidated affiliates(102.9)(72.2)
Taxes paid on behalf of employees for shares withheld(16.4)(15.7)
Contributions from consolidated affiliates57.2 34.9 
Other, net0.7 1.0 
Net cash used in financing activities(240.1)(145.9)
(Decrease) increase in cash, cash equivalents, and restricted cash(190.6)151.3 
Cash, cash equivalents. and restricted cash at beginning of year310.9 159.6 
Cash, cash equivalents, and restricted cash at end of year$120.3 $310.9 
Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period
$224.0 $94.8 
Restricted cash at beginning of period
65.4 57.4 
Restricted cash included in other long-term assets at beginning of period
21.5 7.4 
Cash, cash equivalents, and restricted cash at beginning of period
$310.9 $159.6 
Cash and cash equivalents at end of period
$54.8 $224.0 
Restricted cash at end of period
65.1 65.4 
Restricted cash included in other long-term assets at end of period
0.4 21.5 
Cash, cash equivalents, and restricted cash at end of period
$120.3 $310.9 


10
Encompass Health Corporation and Subsidiaries
Supplemental Information
Earnings Per Share
Q4Year Ended
2021202020212020
(In Millions, Except Per Share Data)
Adjusted EBITDA$252.7 $239.9 $1,028.0 $860.3 
Depreciation and amortization
(65.8)(62.3)(256.6)(243.0)
Interest expense and amortization of debt discounts and fees
(40.1)(46.2)(164.6)(184.2)
Stock-based compensation(11.1)(4.2)(32.8)(29.5)
Loss on disposal or impairment of assets(2.8)(1.0)(0.4)(11.6)
132.9 126.2 573.6 392.0 
Items not indicative of ongoing operating performance:
Loss on early extinguishment of debt
— (2.3)(1.0)(2.3)
Costs associated with the strategic alternatives review(13.3)— (22.9)— 
Costs associated with the Frontier acquisition— — (1.3)— 
Gain on consolidation of former equity method location3.2 — 3.2 2.2 
Change in fair market value of equity securities
0.3 0.1 0.6 0.4 
Government, class action, and related settlements
— — — (2.8)
Payroll taxes on SARs exercise
— — — (1.5)
Pre-tax income123.1 124.0 552.2 388.0 
Income tax expense
(31.5)(38.0)(139.6)(103.8)
Income from continuing operations (1)
$91.6 $86.0 $412.6 $284.2 
Basic shares99.0 98.7 99.0 98.6 
Diluted shares100.2 100.1 100.2 99.8 
Basic earnings per share (1)
$0.92 $0.87 $4.15 $2.87 
Diluted earnings per share (1)
$0.91 $0.86 $4.11 $2.85 
(1)Income from continuing operations attributable to Encompass Health
11
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

Q4Year Ended
2021202020212020
Earnings per share, as reported$0.91 $0.86 $4.11 $2.85 
Adjustments, net of tax:
Government, class action, and related settlements
— — — 0.02 
Costs associated with the strategic alternatives review0.10 — 0.17 — 
Costs associated with the Frontier acquisition— — 0.01 — 
Income tax adjustments
(0.01)0.06 (0.05)0.01 
Loss on early extinguishment of debt
— 0.02 0.01 0.02 
Gain on consolidation of former equity method location(0.02)— (0.02)(0.02)
Payroll taxes on SARs exercise
— — — 0.01 
Adjusted earnings per share*
$0.97 $0.93 $4.23 $2.89 
*    Adjusted EPS may not sum due to rounding.

12
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

For the Three Months Ended December 31, 2021
Adjustments
As ReportedIncome Tax AdjustmentsCosts Associated with the Strategic Alternatives ReviewChange in Fair Market Value of Equity SecuritiesGain on Consolidation of Former Equity Method LocationAs Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA*$252.7 $— $— $— $— $252.7 
Depreciation and amortization(65.8)— — — — (65.8)
Interest expense and amortization of debt discounts and fees
(40.1)— — — — (40.1)
Stock-based compensation(11.1)— — — — (11.1)
Loss on disposal or impairment of assets(2.8)— — — — (2.8)
Costs associated with the strategic alternatives review(13.3)— 13.3 — — — 
Change in fair market value of equity securities
0.3 — — (0.3)— — 
Gain on consolidation of former equity method location3.2 — — — (3.2)— 
Income from continuing operations before income tax expense
123.1 — 13.3 (0.3)(3.2)132.9 
Provision for income tax expense(31.5)(1.3)(3.4)0.1 0.8 (35.3)
Income from continuing operations attributable to Encompass Health
$91.6 $(1.3)$9.9 $(0.2)$(2.4)$97.6 
Diluted earnings per share from continuing operations, as reported**
$0.91 $(0.01)$0.10 $— $(0.02)$0.97 
Diluted shares used in calculation100.2 
*    Reconciliation to GAAP provided on page 17
**    Adjusted EPS may not sum across due to rounding.
13
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

For the Three Months Ended December 31, 2020
Adjustments
As ReportedLoss on Early Extinguishment of DebtIncome Tax AdjustmentsChange in Fair Market Value of Equity SecuritiesAs Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA*$239.9 $— $— $— $239.9 
Depreciation and amortization(62.3)— — — (62.3)
Interest expense and amortization of debt discounts and fees
(46.2)— — — (46.2)
Stock-based compensation(4.2)— — — (4.2)
Loss on disposal or impairment of assets(1.0)— — — (1.0)
Loss on early extinguishment of debt(2.3)2.3 — — — 
Change in fair market value of equity securities
0.1 — — (0.1)— 
Income from continuing operations before income tax expense
124.0 2.3 — (0.1)126.2 
Provision for income tax expense(38.0)(0.6)5.6 — (33.0)
Income from continuing operations attributable to Encompass Health
$86.0 $1.7 $5.6 $(0.1)$93.2 
Diluted earnings per share from continuing operations**
$0.86 $0.02 $0.06 $— $0.93 
Diluted shares used in calculation100.1 

*    Reconciliation to GAAP provided on page 17
**    Adjusted EPS may not sum across due to rounding.

14
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

For the Year Ended December 31, 2021
Adjustments
As ReportedLoss on Early Exting. of DebtIncome Tax AdjustmentsCosts Associated with the Strategic Alternatives ReviewCosts Associated with the Frontier AcquisitionChange in Fair Market Value of Equity SecuritiesGain on Consolidation of Former Equity Method LocationAs Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA*$1,028.0 $— $— $— $— $— $— $1,028.0 
Depreciation and amortization(256.6)— — — — — — (256.6)
Loss on early extinguishment of debt(1.0)1.0 — — — — — — 
Interest expense and amortization of debt discounts and fees(164.6)— — — — — — (164.6)
Stock-based compensation(32.8)— — — — — — (32.8)
Loss on disposal or impairment of assets(0.4)— — — — — — (0.4)
Costs associated with the strategic alternatives review(22.9)— — 22.9 — — — — 
Costs associated with the Frontier acquisition(1.3)— — — 1.3 — — — 
Change in fair market value of equity securities0.6 — — — — (0.6)— — 
Gain on consolidation of former equity method location3.2 — — — — — (3.2)— 
Income from continuing operations before income tax expense
552.2 1.0 — 22.9 1.3 (0.6)(3.2)573.6 
Provision for income tax expense
(139.6)(0.3)(4.9)(5.9)(0.3)0.2 0.8 (150.0)
Income from continuing operations attributable to Encompass Health
$412.6 $0.7 $(4.9)$17.0 $1.0 $(0.4)$(2.4)$423.6 
Diluted earnings per share from continuing operations, as reported**
$4.11 $0.01 $(0.05)$0.17 $0.01 $— $(0.02)$4.23 
Diluted shares used in calculation
100.2 
*    Reconciliation to GAAP provided on page 17
**    Adjusted EPS may not sum across due to rounding.
15
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

For the Year Ended December 31, 2020
Adjustments
As ReportedGov't, Class Action, & Related SettlementsLoss on Early Exting. of DebtIncome Tax AdjustmentsChange in Fair Market Value of Equity SecuritiesGain on Consolidation of Former Equity Method LocationPayroll Taxes on SARs ExerciseAs Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA*$860.3 $— $— $— $— $— $— $860.3 
Depreciation and amortization(243.0)— — — — — — (243.0)
Interest expense and amortization of debt discounts and fees(184.2)— — — — — — (184.2)
Stock-based compensation(29.5)— — — — — — (29.5)
Loss on disposal or impairment of assets(11.6)— — — — — — (11.6)
Loss on early extinguishment of debt(2.3)— 2.3 — — — — — 
Gain on consolidation of former equity method location2.2 — — — — (2.2)— — 
Change in fair market value of equity securities0.4 — — — (0.4)— — — 
Payroll taxes on SARs exercise(1.5)— — — — — 1.5 — 
Government, class action, and related settlements(2.8)2.8 — — — — — — 
Income from continuing operations before income tax expense388.0 2.8 2.3 — (0.4)(2.2)1.5 392.0 
Provision for income tax
expense
(103.8)(0.7)(0.6)1.0 0.1 0.6 (0.4)(103.8)
Income from continuing operations attributable to Encompass Health$284.2 $2.1 $1.7 $1.0 $(0.3)$(1.6)$1.1 $288.2 
Diluted earnings per share from continuing operations**$2.85 $0.02 $0.02 $0.01 $— $(0.02)$0.01 $2.89 
Diluted shares used in calculation99.8 

*    Reconciliation to GAAP provided on page 17
**    Adjusted EPS may not sum across due to rounding.
16
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Income to Adjusted EBITDA

 For the Three Months Ended December 31,For the Year Ended December 31,
 2021202020212020
(In Millions)
Net income$115.7 $111.7 $517.2 $368.8 
Loss from discontinued operations, net of tax, attributable to Encompass Health— — 0.4 — 
Net income attributable to noncontrolling interests(24.1)(25.7)(105.0)(84.6)
Provision for income tax expense31.5 38.0 139.6 103.8 
Interest expense and amortization of debt discounts and fees
40.1 46.2 164.6 184.2 
Depreciation and amortization65.8 62.3 256.6 243.0 
Government, class action, and related settlements— — — 2.8 
Loss on early extinguishment of debt— 2.3 1.0 2.3 
Loss on disposal or impairment of assets2.8 1.0 0.4 11.6 
Stock-based compensation11.1 4.2 32.8 29.5 
Costs associated with the strategic alternatives review13.3 — 22.9 — 
Costs associated with the Frontier acquisition— — 1.3 — 
Gain on consolidation of former equity method location(3.2)— (3.2)(2.2)
Change in fair market value of equity securities(0.3)(0.1)(0.6)(0.4)
Payroll taxes on SARs exercise— — — 1.5 
Adjusted EBITDA$252.7 $239.9 $1,028.0 $860.3 
Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations
Before Income Tax Expense
For the Three Months Ended December 31,For the Year Ended December 31,
2021202020212020
(In Millions)
Total segment Adjusted EBITDA$288.9 $273.5 $1,168.3 $986.3 
General and administrative expenses(60.6)(37.8)(197.3)(155.5)
Depreciation and amortization(65.8)(62.3)(256.6)(243.0)
Loss on disposal or impairment of assets(2.8)(1.0)(0.4)(11.6)
Government, class action, and related settlements— — — (2.8)
Loss on early extinguishment of debt— (2.3)(1.0)(2.3)
Interest expense and amortization of debt discounts and fees
(40.1)(46.2)(164.6)(184.2)
Net income attributable to noncontrolling interests24.1 25.7 105.0 84.6 
Change in fair market value of equity securities0.3 0.1 0.6 0.4 
Gain on consolidation of former equity method location3.2 — 3.2 2.2 
Payroll taxes on SARs exercise— — — (1.5)
Income from continuing operations before income tax expense
$147.2 $149.7 $657.2 $472.6 

17
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

For the Three Months Ended December 31,For the Year Ended December 31,
2021202020212020
(In Millions)
Net cash provided by operating activities
$123.8 $279.7 $715.8 $704.7 
Interest expense and amortization of debt discounts and fees
40.1 46.2 164.6 184.2 
Equity in net income of nonconsolidated affiliates
1.1 1.0 4.0 3.5 
Net income attributable to noncontrolling interests in continuing operations
(24.1)(25.7)(105.0)(84.6)
Amortization of debt-related items
(2.0)(2.1)(7.8)(7.2)
Distributions from nonconsolidated affiliates
(0.2)(1.0)(2.9)(3.8)
Current portion of income tax expense (benefit)8.1 (20.1)111.8 51.4 
Change in assets and liabilities91.0 (40.4)118.0 7.3 
Cash (provided by) used in operating activities of discontinued operations(0.1)— 0.5 0.2 
Costs associated with the strategic alternatives review13.3 — 22.9 — 
Costs associated with the Frontier acquisition— — 1.3 — 
Payroll taxes on SARs exercise— — — 1.5 
Change in fair market value of equity securities(0.3)(0.1)(0.6)(0.4)
Other2.0 2.4 5.4 3.5 
Adjusted EBITDA$252.7 $239.9 $1,028.0 $860.3 

18
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow
For the Three Months Ended December 31,For the Year Ended December 31,
2021202020212020
(In Millions)
Net cash provided by operating activities$123.8 $279.7 $715.8 $704.7 
Impact of discontinued operations(0.1)— 0.5 0.2 
Net cash provided by operating activities of continuing operations
123.7 279.7 716.3 704.9 
Capital expenditures for maintenance(52.9)(47.4)(138.8)(154.9)
Distributions paid to noncontrolling interests of consolidated affiliates
(25.1)(19.3)(102.9)(72.2)
Items not indicative of ongoing operating performance:
Transaction costs and related assumed liabilities
16.0 — 24.2 — 
Cash paid for SARs exercise (inclusive of payroll taxes)— — — 102.1 
Adjusted free cash flow$61.7 $213.0 $498.8 $579.9 
For the three months ended December 31, 2021, net cash used in investing activities was $220.7 million and resulted primarily from capital expenditures. Net cash provided by financing activities during the three months ended December 31, 2021 was $42.3 million and resulted primarily from net debt borrowings offset by cash dividends paid on common stock and distributions to noncontrolling interests of consolidated affiliates.
For the three months ended December 31, 2020, net cash used in investing activities was $142.7 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended December 31, 2020 was $354.2 million and resulted primarily from net debt repayments, cash dividends paid on common stock, and distributions to noncontrolling interests of consolidated affiliates.
For the year ended December 31, 2021, net cash used in investing activities was $666.3 million and primarily resulted from capital expenditures and the acquisition of assets from Frontier Home Health and Hospice. Net cash used in financing activities during the year ended December 31, 2021 was $240.1 million and primarily resulted from net debt payments, cash dividends paid on common stock, and distributions to noncontrolling interests of consolidated affiliates.
For the year ended December 31, 2020, net cash used in investing activities was $407.5 million and primarily resulted from capital expenditures. Net cash used in financing activities during the year ended December 31, 2020 was $145.9 million and primarily resulted from the issuance of senior notes in May and October 2020 offset by the redemption of the Company's 5.75% Senior Notes due 2024, the purchase of one-third of the rollover shares held by members of the home health and hospice management team, dividends paid common stock, and distributions paid to noncontrolling interests of consolidated affiliates.
19
Encompass Health Corporation and Subsidiaries
Forward-Looking Statements
Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the timing and effects, such as the tax-free treatment and the incremental costs, of the spin-off and rebranding of the home health and hospice business and its impact on the business model, outlook and guidance, the nature of the COVID-19 pandemic and its impact on Encompass Health's business and financial assumptions, legislative and regulatory developments, financial guidance, balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information, involve a number of risks and uncertainties, and relate to, among other things, future events, Encompass Health's plan to repurchase its debt or equity securities, dividend strategies, effective income tax rates, its business strategy, its financial plans, its future financial performance, its projected business results or model, its ability to return value to shareholders, its projected capital expenditures, its leverage ratio, its acquisition opportunities, and the impact of future legislation or regulation. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, the possibility that the Company may not be able to realize higher values for its home health and hospice business through strategic transactions; the possibility that the Company may decide not to undertake a transaction following the review of strategic alternatives or that it is not able to consummate any proposed transactions resulting from the review due to, among other things, market, regulatory and other factors; the potential for disruption to the Company's business resulting from the review of strategic alternatives or the undertaking of any transactions following the review; the continued spread of COVID-19, including the speed, depth, geographic reach and duration of the spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; actions to be taken by the Company in response to the pandemic; the legal, regulatory and administrative developments that occur at the federal, state and local levels; the Company's infectious disease prevention and control efforts; the demand for the Company's services, including based on any downturns in the economy, consumer confidence, or the capital markets and unemployment among family members; the price of Encompass Health's common stock as it affects the Company's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; any adverse effects on Encompass Health's stock price resulting from the integration of acquired operations; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability as well as unforeseen issues, if any, related to integration of acquired systems; the ability to successfully integrate acquired operations, including realization of anticipated tax benefits, revenues, and cost savings, minimizing the negative impact on margins arising from the changes in staffing and other operating practices, and avoidance of unforeseen exposure to liabilities; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction (such as the Patient-Driven Groupings Model for home health) and Encompass Health's ability to adapt operations to those changes; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and
20
Encompass Health Corporation and Subsidiaries
Forward-Looking Statements
retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by the pandemic, and the impact on Encompass Health's labor expenses from potential union activity and staffing shortages; general conditions in the economy and capital markets, including any instability or uncertainty related to armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in the costs of defending and insuring against alleged professional liability claims, including claims associated with patient and employee exposures to COVID-19, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2021, when filed.
21
Earnings Call February 2, 2022 Supplemental information 2021 Fourth Quarter

 
Encompass Health 2 The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect Encompass Health’s current outlook, views and plans with respect to future events, including the timing and effects, such as the tax-free treatment and the incremental costs, of the spin-off and rebranding of the home health and hospice business and its impact on the business model, outlook and guidance, the COVID-19 pandemic and its effects, legislative and regulatory developments, strategy, capital expenditures, acquisition and other development activities, cyber security, dividend strategies, repurchases of securities, effective tax rates, financial performance, financial assumptions, business model, balance sheet and cash flow plans, market share, development of new information tools and models, and shareholder value-enhancing transactions. These estimates, projections and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material. There can be no assurance any estimates, projections or forward-looking information will be realized. All such estimates, projections and forward-looking information speak only as of the date hereof. Encompass Health undertakes no duty to publicly update or revise the information contained herein. You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the earnings release attached as Exhibit 99.1 to the Company’s Form 8-K dated February 1, 2022 (the “Q4 Earnings Release Form 8-K”), the Form 10-K for the year ended December 31, 2021, when filed, the Form 10-K for the year ended December 31, 2020, the Form 10-Q for the quarter ended September 30, 2021, and in other documents Encompass Health previously filed with the SEC, many of which are beyond Encompass Health’s control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein. Note regarding presentation of non-GAAP financial measures The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, leverage ratios, adjusted earnings per share, and adjusted free cash flow. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. The Q4 Earnings Release Form 8-K, to which the following presentation is attached as Exhibit 99.2, provides further explanation and disclosure regarding Encompass Health’s use of non-GAAP financial measures and should be read in conjunction with this supplemental information. Forward-looking statements

 
Encompass Health 3 2021 Year in review ............................................................................................................................................................................. 4 Spin-off of Enhabit Home Health & Hospice ................................................................................................................................... 5-7 Key takeaways ....................................................................................................................................................................................... 8 Q4 2021 Summary ................................................................................................................................................................................. 9 Inpatient rehabilitation segment ...................................................................................................................................................... 10-12 Home health & hospice segment ....................................................................................................................................................... 13-17 Consolidated Adjusted EBITDA .......................................................................................................................................................... 18 Earnings per share ................................................................................................................................................................................ 19-20 Adjusted free cash flow ....................................................................................................................................................................... 21 2021 Guidance trend ........................................................................................................................................................................... 22 Guidance and considerations for 2022 ............................................................................................................................................ 23-24 2022-2026 Growth targets ................................................................................................................................................................. 25 Adjusted free cash flow assumptions ............................................................................................................................................... 26 Uses of free cash flow .......................................................................................................................................................................... 27 Appendix Map of locations ..................................................................................................................................................................................... 29 Expansion activity ................................................................................................................................................................................. 30 Clinical collaboration ........................................................................................................................................................................... 31 Pre-payment claims denials - inpatient rehabilitation segment ............................................................................................... 32 Debt maturity profile and schedule ................................................................................................................................................. 33-34 New-store/same-store growth ........................................................................................................................................................... 35-37 Payment sources (percent of revenues) ......................................................................................................................................... 38 Inpatient rehabilitation operational metrics ................................................................................................................................. 39 Home health & hospice operational metrics .................................................................................................................................. 40 Share information ................................................................................................................................................................................. 41 Segment operating results .................................................................................................................................................................. 42-43 Reconciliations to GAAP ...................................................................................................................................................................... 44-52 End notes ................................................................................................................................................................................................ 53-54 Table of contents

 
Encompass Health 4 2021 Year in review u Strong financial performance for 2021 in spite of challenges related to Alpha, Delta, and Omicron variants Ÿ Consolidated revenue growth of 10.3% ü Inpatient rehabilitation revenue increased 12.6%. ü Home health and hospice revenue increased 2.6%. Ÿ Consolidated Adjusted EBITDA growth of 19.5% ü Inpatient rehabilitation Adjusted EBITDA increased 16.3%. ü Home health and hospice Adjusted EBITDA increased 29.5%. u Continued growth for both segments Ÿ Inpatient rehabilitation hospital total licensed bed growth for 2021 of 4.4% ü Opened 8 de novo IRFs (350 beds) and added 117 licensed beds to existing hospitals ü Anticipate opening 10 de novo IRFs (~446 beds) and adding ~100 beds to existing hospitals in 2022 Ÿ Home health and hospice invested $102 million in acquisitions and opened 3 de novo locations. ü Acquired Frontier Home Health & Hospice, Hospice of Bozeman Health, and Baptist Health South Florida ü De novo hospice openings in Las Cruces, NM; Abilene, TX; and Tyler, TX ü Anticipate 10 de novo openings in 2022 u Both business segments well-positioned for sustained future growth Ÿ Strong demographic tailwinds Ÿ Multi-faceted growth strategies Ÿ Pending spin-off of Enhabit Home Health & Hospice (see page 5)

 
Encompass Health 5 Spin-off of Enhabit Home Health & Hospice u Encompass Health plans to spin off its home health and hospice business into an independent publicly traded company Ÿ The spin-off is expected to be tax free to EHC shareholders. (A Private Letter Ruling request has been filed with the IRS.) Ÿ The spin-off is expected to be completed by the end of Q2 2022 and will be preceded with a public filing of a Form 10 with the SEC. u The home health and hospice business will be rebranded as Enhabit Home Health & Hospice Ÿ The rebranding of branches will begin in mid-April and is expected to be largely completed by the effective date of the spin-off. Ÿ Certain administrative services will be provided by Encompass Health to Enhabit Home Health & Hospice for up to one year following the spin-off under a transition services agreement. u Financial considerations for the spin-off transaction Ÿ The company anticipates leverage (Debt to Adjusted EBITDA) at the effective date of approximately 3.0-3.25x at Enhabit Home Health & Hospice and 3.25-3.5x at Encompass Health Corporation. Ÿ Establishing Enhabit Home Health & Hospice as a stand-alone entity will result in an estimated $26-$28 million of incremental annualized G&A costs, and an estimated $5-$10 million* reduction in annualized G&A expenses for Encompass Health. Ÿ Rebranding expenses for Enhabit Home Health & Hospice are expected to be $10-$13 million in operating expenses and $3-$5 million in capital expenditures. These expenses are expected to be incurred in 2022. *Position within this range is dependent, among other things, on the scope and duration of a transition services agreement.

 
Encompass Health 6 Home health & hospice rebranding The future of home-based healthcare is here Committed to delivering a better way to care for our patients and their loved ones One of Modern Healthcare’s Best Places to Work Industry leader in advanced technologies and predictive analytics Learn more about Enhabit at www.ehab.com

 
Encompass Health 7 Enhabit Home Health & Hospice Home Health Overview ~200,600 2021 Home Health Total Admissions 251 Home Health Locations 34 States 4th Largest Provider of Medicare-Certified Skilled Home Health Services Hospice Overview ~13,100 2021 Hospice Admissions 96 Hospice Locations 22 States Home Health & Hospice Overview ~10,900 Employees ~$1.1 Billion in revenue 347 locations Portfolio as of 12/31/21 Home Health Locations Hospice Locations

 
Encompass Health 8 Q4 2021 Key takeaways u Balance sheet - see debt schedule and maturity profile on pages 33-34 Ÿ Net leverage ratio of 3.1x at quarter end u Shareholder and other distributions Ÿ Paid quarterly cash dividend of $0.28 per share in October 2021 Ÿ Declared a $0.28 per share quarterly cash dividend in October 2021 (paid in January 2022) u Solid consolidated financial performance in Q4 in spite of Delta and Omicron surges Ÿ Consolidated revenue growth of 8.6% Ÿ Consolidated Adjusted EBITDA growth of 5.3% u Strong revenue and Adjusted EBITDA growth in IRF segment Ÿ Revenue growth of 11.7% driven by 9.6% discharge growth (6.0% same store) Ÿ Adjusted EBITDA growth of 8.4% (margin impacted by elevated staffing costs) Ÿ Average daily census increased 8.7% to a new high of 7,100. u Total admissions growth of 4.7% in home health Ÿ Continued growth of non-episodic admissions Ÿ Cost of services increased primarily due to industry-wide staffing challenges. Ÿ Continued positive trends in nursing hires and admissions from new referral sources

 
Encompass Health 9 Q4 2021 Summary Q4 Full Year ($ in millions) 2021 2020 %  2021 2020 %  Encompass Health Consolidated Net operating revenues $ 1,318.7 $ 1,214.4 8.6 % $ 5,121.6 $ 4,644.4 10.3 % Adjusted EBITDA $ 252.7 $ 239.9 5.3 % $ 1,028.0 $ 860.3 19.5 % Adjusted EPS $ 0.97 $ 0.93 4.3 % $ 4.23 $ 2.89 46.4 % Adjusted free cash flow* $ 61.7 $ 213.0 (71.0) % $ 498.8 $ 579.9 (14.0) % Inpatient Rehabilitation Segment Net operating revenues $ 1,042.6 $ 933.1 11.7 % $ 4,015.0 $ 3,566.2 12.6 % Adjusted EBITDA $ 236.3 $ 218.0 8.4 % $ 956.8 $ 823.0 16.3 % Home Health and Hospice Segment Net operating revenues $ 276.1 $ 281.3 (1.8) % $ 1,106.6 $ 1,078.2 2.6 % Adjusted EBITDA $ 52.6 $ 55.5 (5.2) % $ 211.5 $ 163.3 29.5 % *Refer to page 21 for a discussion of year-to-year change. Reconciliations to GAAP provided on pages 44-52

 
Encompass Health 10 Inpatient rehabilitation segment Q4 Revenue growth of 11.7% u Inpatient revenue growth resulted from increased volumes and pricing. Ÿ Total discharge growth of 9.6%, inclusive of same-store growth of 6.0% Ÿ Growth in net patient revenue per discharge of 1.2% primarily resulted from an increase in reimbursement rates partially offset by payor mix (faster growth in Managed Care and Medicare Advantage). u The increase in outpatient and other revenue included an increase of $9.7 million in provider tax revenues ($18.7 million in Q4 2021 vs. $9.0 million in Q4 2020). Q4 Adjusted EBITDA increased 8.4% u Adjusted EBITDA growth primarily resulted from revenue growth. u Elevated staffing costs: Ÿ Higher agency staffing to meet increased patient volumes plus sign-on and shift bonuses Ÿ Average staffing cost per FTE increased 6.4%. u Operating leverage drove a 90 bp decrease in hospital operating expenses as a percent of revenue. See operating metrics on page 39. Reconciliations to GAAP provided on pages 44-52

 
Encompass Health 11 Inpatient rehabilitation segment - revenue Q4 Q4 Favorable/ ($ in millions) 2021 2020 (Unfavorable) Net operating revenues: Inpatient $ 1,015.2 $ 914.9 11.0% Outpatient and other 27.4 18.2 50.5% Total segment revenue $ 1,042.6 $ 933.1 11.7% (Actual Amounts) Discharges 50,977 46,503 9.6% Same-store discharge growth 6.0% Net patient revenue per discharge $ 19,915 $ 19,674 1.2% Revenue reserves related to bad debt as a percent of revenue 2.3 % 2.2 % 10 basis points Revenue reserves related to bad debt as a percent of revenue increased 10 bps to 2.3%, primarily due to the impact of the payor mix shift to Managed Care and Medicare Advantage, which have a slower claims processing time compared to Medicare. Ÿ Revenue reserves in Q4 2021 include $2.5M associated with a CMS settlement of a limited pool of previously denied claims. Ÿ Revenue reserves in Q4 2020 included $4.5M related to an update of our reserves for previously denied claims.

 
Encompass Health 12 Inpatient rehabilitation segment - Adjusted EBITDA Q4 % of Revenue Q4 % of Revenue($ in millions) 2021 2020 Net operating revenues $ 1,042.6 $ 933.1 Operating expenses: Salaries and benefits (572.4) 54.9 % (495.1) 53.1 % Other operating expenses(a) (151.1) 14.5 % (140.2) 15.0 % Supplies (48.1) 4.6 % (44.1) 4.7 % Occupancy costs (14.5) 1.4 % (15.4) 1.7 % Hospital operating expenses (213.7) 20.5 % (199.7) 21.4 % Other income(b) 2.4 4.1 Equity in nonconsolidated affiliates 1.0 0.9 Noncontrolling interests (23.6) (25.3) Segment Adjusted EBITDA $ 236.3 $ 218.0 Percent change 8.4 % In arriving at Adjusted EBITDA, the following were excluded: (a) Loss on disposal or impairment of assets $ 2.9 $ 1.0 (b) Change in fair market value of equity securities $ (0.3) $ (0.1) Reconciliations to GAAP provided on pages 44-52 Other operating expenses included an increase of $4.7 million in provider tax expense ($13.9 million in Q4 2021 vs. $9.2 million in Q4 2020).

 
Encompass Health 13 Home health and hospice segment Home health total admissions increased 4.7%; same store growth of 2.4% u Home health total admissions increased 4.7% in Q4; increased 3.3% in 2021. Ÿ Non-episodic admissions increased 67.6% in Q4; increased 28.1% in 2021. Ÿ Episodic admissions declined 7.2% in Q4. ü Approximately 50% of the decline related to the conversion of admissions to non-episodic under a large managed care contract initiated in February 2021. Ÿ Lost a minimum of ~1,700 home health admissions in Q4 as a result of staffing constraints. Hospice admissions decreased 3.7% u Hospice admissions decreased 3.7% in Q4; increased 1.8% in 2021. Ÿ Same store hospice admissions decreased 14.5%. Ÿ Staffing constraints impacted admissions at larger branches with historically higher ADCs. Segment revenue decreased 1.8% u Home health revenue decreased primarily from a reduction in episodic admissions, partially offset by the continued growth in non-episodic admissions and increased reimbursement rates. u Home health revenue per episode increased 4.4% primarily due to an increase in reimbursement rates, the mix between early and late payment periods, the mix of patients coming from institutional settings and a decrease in LUPAs. u Non-episodic rate per visit increased 1.6% primarily due to an increase in reimbursement rates. u Hospice revenue per patient day increased 1.9% primarily due to an increase in reimbursement rates. See operating metrics on page 40.

 
Encompass Health 14 Home health and hospice segment (continued) Adjusted EBITDA decreased 5.2% u Adjusted EBITDA decreased primarily due to the higher costs of services related to industry- wide staffing challenges. u Home health cost per visit increased ~9% primarily due to lower clinical productivity, market rate increases for nurses, increased costs associated with mileage reimbursement and increased use of agency staffing. Ÿ Lower clinical productivity primarily resulted from staff in quarantine and lower productivity assocated with new hires. Ÿ Costs associated with mileage reimbursement increased due to staff covering larger geographic areas and increased gas prices. Demand for home healthcare continues to rise u We continue to experience year-over-year growth in patient referrals. Ÿ Total home health patient referrals grew 11.6% in 2021 vs. 2020. Ÿ Added ~3,300 new referral sources in Q4 2021 See operating metrics on page 40.

 
Encompass Health 15 Home health and hospice segment (continued) Recruiting, retention, and labor trends u While we have continued to see staffing limitations across homecare, we are making great progress hiring nurses. Ÿ Increased nursing staff by 133 full-time employees in Q4 2021, 70 more than in Q4 2020 Ÿ Increased nursing staff by 327 full-time employees in 2021, as compared to a decrease of 2 nursing staff in 2020 Ÿ Productivity should improve as quarantines subside and new hires onboard and become acclimated in 2022. u Employee engagement remains positive; continued to score above healthcare benchmarks in most recent survey u Investing in resources to focus on retention; hired Chief Human Resources Officer and VP of Talent Acquisition u Longer term adjustments: Ÿ Increased our hiring incentives through salary market adjustments, more flexible work schedules and sign-on bonuses See operating metrics on page 40.

 
Encompass Health 16 Home health and hospice segment - revenue Q3 Q3 Favorable/ ($millions) 2021 2020 (Unfavorable) Net operating revenues: Home health revenue $ 219.9 $ 224.8 (2.2) % Hospice revenue 50.6 48.0 5.4 % Total segment revenue $ 270.5 $ 272.8 (0.8) % Home Health Metrics (Actual Amounts) Episodic admissions 40,215 42,476 (5.3) % Same-store episodic admissions growth (5.4) % Episodes 66,435 68,652 (3.2) % Same-store episode growth (3.4) % Revenue per episode $ 2,923 $ 2,909 0.5 % Q4 Q4 Favorable/ ($ in millions) 2021 2020 (Unfavorable) Net operating revenues: Home health revenue $ 224.0 $ 227.7 (1.6) % Hospice revenue 52.1 53.6 (2.8) % Total segment revenue $ 276.1 $ 281.3 (1.8) % Home Health Starts of care: Total admissions 50,817 48,533 4.7 % Same-store total admissions growth 2.4 % Total recertifications 32,621 33,497 (2.6) % Total starts of care 83,438 82,030 1.7 % Episodic admissions 37,908 40,830 (7.2) % Same-store episodic admissions growth (9.5) % Episodic recertifications 27,273 30,064 (9.3) % Total episodic starts of care 65,181 70,894 (8.1) % Revenue per episode $ 3,010 $ 2,883 4.4 % Hospice Admissions: Same store 2,861 3,348 (14.5) % New store 362 — 10.8 % Total admissions 3,223 3,348 (3.7) %

 
Encompass Health 17 Q4 % of Revenue Q4 % of Revenue($ in millions) 2021 2020 Net operating revenues $ 276.1 $ 281.3 Cost of services (124.6) 45.1 % (121.9) 43.3 % Support and overhead costs (98.5) 35.7 % (103.6) 36.8 % Operating expenses(a) (223.1) 80.8 % (225.5) 80.2 % Other income(b) — — Equity in net income of nonconsolidated affiliates 0.1 0.1 Noncontrolling interests (0.5) (0.4) Segment Adjusted EBITDA $ 52.6 $ 55.5 Percent change (5.2) % In arriving at Adjusted EBITDA, the following were excluded: (a) Gain on disposal of assets $ (0.1) $ — (b) Gain on consolidation of former equity method location(1) $ (3.2) $ — Home health and hospice segment - Adjusted EBITDA Reconciliations to GAAP provided on pages 44-52 Refer to pages 53-54 for end notes. Adjusted EBITDA for Q4 2021 benefited from a $6.3 million decline in employee medical insurance costs, in part due to a change in the Company’s medical plan. For 2021, Adjusted EBITDA benefited from a $2.3 million decline in employee medical insurance costs.

 
Encompass Health 18 Consolidated Adjusted EBITDA ($ in millions) Q4 2021 % of Consolidated Revenue Q4 2020 % of Consolidated Revenue Inpatient rehabilitation segment Adjusted EBITDA $ 236.3 $ 218.0 Home health and hospice segment Adjusted EBITDA 52.6 55.5 General and administrative expenses* (36.2) 2.7% (33.6) 2.8% Consolidated Adjusted EBITDA $ 252.7 $ 239.9 Percentage change 5.3 % Reconciliations to GAAP provided on pages 44-52 Consolidated Adjusted EBITDA for the quarter of $252.7 million u General and administrative expenses decreased as a percent of consolidated revenue due to the increased revenue base year-over-year. * General and administrative expenses in the above table exclude stock compensation of $11.1 million and $4.2 million for Q4 2021 and Q4 2020, respectively, as well as $13.3 million in costs associated with the strategic alternatives review of our home health and hospice business for Q4 2021.

 
Encompass Health 19 Earnings per share - as reported Q4 Year Ended ($ in millions, except per share data) 2021 2020 2021 2020 Adjusted EBITDA $ 252.7 $ 239.9 $ 1,028.0 $ 860.3 Depreciation and amortization (65.8) (62.3) (256.6) (243.0) Interest expense and amortization of debt discounts and fees (40.1) (46.2) (164.6) (184.2) Stock-based compensation (11.1) (4.2) (32.8) (29.5) Loss on disposal or impairment of assets (2.8) (1.0) (0.4) (11.6) 132.9 126.2 573.6 392.0 Items not indicative of ongoing operating performance: Loss on early extinguishment of debt(2)(17) — (2.3) (1.0) (2.3) Costs associated with the strategic alternatives review (13.3) — (22.9) — Costs associated with the Frontier acquisition — — (1.3) — Gain on consolidation of former equity method location(1)(3) 3.2 — 3.2 2.2 Change in fair market value of equity securities 0.3 0.1 0.6 0.4 Government, class action, and related settlements(4) — — — (2.8) Payroll taxes on SARs exercise(5) — — — (1.5) Pre-tax income 123.1 124.0 552.2 388.0 Income tax expense (31.5) (38.0) (139.6) (103.8) Income from continuing operations* $ 91.6 $ 86.0 $ 412.6 $ 284.2 Diluted shares (see page 41) 100.2 100.1 100.2 99.8 Diluted earnings per share* $ 0.91 $ 0.86 $ 4.11 $ 2.85 u The increase in EPS in the fourth quarter of 2021 and the full-year 2021 primarily resulted from increased Adjusted EBITDA. * Earnings per share are determined using income from continuing operations attributable to Encompass Health. Refer to pages 53-54 for end notes.

 
Encompass Health 20 Adjusted earnings per share(6) * Adjusted EPS may not sum due to rounding. See complete calculations of adjusted earnings per share on pages 49-52. Refer to pages 53-54 for end notes. Q4 Year Ended 2021 2020 2021 2020 Earnings per share, as reported $ 0.91 $ 0.86 $ 4.11 $ 2.85 Adjustments, net of tax: Government, class action, and related settlements(4) — — — 0.02 Costs associated with the strategic alternatives review 0.10 — 0.17 — Costs associated with the Frontier acquisition — — 0.01 — Income tax adjustments (0.01) 0.06 (0.05) 0.01 Loss on early extinguishment of debt(2)(17) — 0.02 0.01 0.02 Gain on consolidation of former equity method location(1)(3) (0.02) — (0.02) (0.02) Payroll taxes on SARs exercise(5) — — — 0.01 Adjusted earnings per share* $ 0.97 $ 0.93 $ 4.23 $ 2.89 u Adjusted earnings per share removes from the GAAP earnings per share calculation the impact of items the Company believes are non-indicative of its ongoing operating performance.

 
Encompass Health 21 579.9 167.7 (188.4) 20.2 (96.7) 16.1 498.8 Adjusted Free Cash Flow FY 2020 Adjusted EBITDA Working capital and other Cash interest payments Cash tax payments, net of refunds Maintenance capital expenditures Adjusted Free Cash Flow FY 2021 2021 Adjusted free cash flow(7) Reconciliations to GAAP provided on pages 44-52 Refer to pages 53-54 for end notes. u Adjusted free cash flow was lower in 2021 than in 2020 due to increased working capital and cash tax payments. u Increased working capital primarily resulted from the deferral of 2020 payroll taxes based on government relief efforts in 2020 (half of which was paid in Dec. 2021, with the remaining half due in Dec. 2022). u Increased cash tax payments in 2021 due to higher year-over-year book income and tax relief in 2020 associated with the CARES Act ($ in millions)

 
Encompass Health 22 2021 Full-year guidance trend and actual results *Updated guidance on April 27, 2021, primarily due to extension of sequestration suspension for Q2 - Q4 2021 **Updated guidance on July 27, 2021, primarily to reflect strong YTD operating trends ***Updated guidance on October 27, 2021, primarily to reflect challenges related to the Delta variant Refer to pages 53-54 for end notes. Initial Guidance Updated Guidance* Updated Guidance** Updated Guidance*** 2021 Actuals ($ in millions, except per share data) January 26, 2021 April 27, 2021 July 27, 2021 October 27, 2021 Net Operating Revenue $5,000 to $5,170 $5,060 to $5,230 $5,100 to $5,250 $5,080 to $5,130 $5,122 Adjusted EBITDA (8) $925 to $955 $1,000 to $1,030 $1,050 to $1,070 $1,025 to $1,045 $1,028 Adjusted earnings per share from continuing operations attributable to Encompass Health (6) $3.31 to $3.53 $3.94 to $4.16 $4.32 to $4.47 $4.23 to $4.38 $4.23

 
Encompass Health 23 2022 Guidance The Company's 2022 guidance assumes the continuation of the current structure of the business for 2022. Refer to pages 53-54 for end notes. 2021 Actuals 2022 Guidance* ($ in millions, except per share data) Net Operating Revenue $5,122 $5,380 to $5,500 Adjusted EBITDA (8) $1,028 $1,015 to $1,065 Adjusted earnings per share from continuing operations attributable to Encompass Health (6) $4.23 $3.83 to $4.19 *Not inclusive of any costs incurred in 2022 related to the preparations for the planned spin-off of Enhabit Home Health & Hospice including rebranding, professional fees, or personnel additions specifically required for an independent public company.

 
Encompass Health 24 2022 Guidance considerations Inpatient Rehabilitation u Estimated increase of 1.9% in Medicare pricing prior to resumption of sequestration u Revenue reserves related to bad debt of 1.8% to 2.0% of net operating revenues u Salaries and benefits per FTE (inclusive of agency staffing costs, sign-on and shift bonuses) increase of 3% to 4% u Pre-opening and new-store ramp-up costs of $10 million to $13 million Home Health and Hospice u Estimated increase of 3.4% in Medicare pricing for home health prior to resumption of sequestration u Estimated increase of 2.0% in Medicare pricing for hospice prior to resumption of sequestration u Cost per visit increase of 4% to 5% for home health u Cost per patient day increase of 3% to 4% for hospice u Incremental investment of $2 million to $3 million for de novo locations Consolidated u Medicare pricing increases will be affected by phased in resumption of sequestration: 1% in Q2, 2% in Q3 and Q4. u Staffing constraints and elevated costs are expected to continue into 2022 with improvement skewed towards the second half of the year. u Guidance is not inclusive of any costs incurred in 2022 related to the preparations for the planned spin-off of Enhabit Home Health & Hospice including rebranding, professional fees, or personnel additions specifically required for an independent public company.

 
Encompass Health 25 2022-2026 Growth targets INPATIENT REHABILITATION HOME HEALTH AND HOSPICE 6 to 10 De novos per year 100 to 150 bed additions per year 6% to 8% Discharge CAGR 10%+ Home Health admissions CAGR 10% to 15% Hospice admissions CAGR $50 million to $100 million Acquisitions per year Strong and sustainable business fundamentals Ÿ Strong demographic tailwinds Ÿ Multi-faceted growth strategies Ÿ Highly fragmented post-acute sectors present acquisition and joint venture opportunities. Ÿ Consistent delivery of high-quality, cost-effective, facility-based and home-based care Ÿ Economies related to scale and market density Ÿ Substantial cash flow generation Reconciliations to GAAP provided on pages 44-52

 
Encompass Health 26 Adjusted free cash flow(7) assumptions Certain cash flow items ($ in millions) 2021 Actuals 2022 Assumptions Cash interest payments (net of amortization of debt discounts and fees) $156.8 $150 to $160 Cash payments for income taxes, net of refunds $129.6 $125 to $140 Working capital and other $104.0 $80 to $100 Maintenance CAPEX $138.8 $200 to $250 Adjusted free cash flow $498.8 $365 to $510 u Increase in cash payments for taxes due to higher book income u Modest increase in working capital due to timing of collections u Increased maintenance CAPEX related to carryover projects from 2021 due to construction supply chain challenges; additional spending for equipment replacement, and improvements to existing hospitals u Cash interest payments expected to be flat due to lower average interest rate in 2021 with the redemption of $200 million of 5.125% Senior Notes due 2023 in Q2 2021 partially offset by increased short term borrowing rates in 2022 Reconciliations to GAAP provided on pages 44-52 Refer to pages 53-54 for end notes.

 
Encompass Health 27 Uses of free cash flow ($ in millions) 2021 Actuals 2022 Assumptions Growth in core business IRF bed expansions $48.6 $40 to $50 New IRFs - De novos 314.9 320 to 340 - Acquisitions 1.1 opportunistic - Replacement IRFs and other 48.9 10 to 20 Home health and hospice acquisitions* 117.5 50 to 100 $531.0 $420 to $510 Debt reduction Debt redemptions (borrowings), net $2.2 opportunistic Shareholder and other distributions Cash dividends on common stock 112.4 ~$112 Common stock repurchases — opportunistic ~$198 million authorization remaining as of December 31, 2021(9) See the debt schedule on page 34. Refer to pages 53-54 for end notes. Quarterly cash dividend currently set at $0.28 per common share *Includes approximately $16 million related to an acquisition effective on January 1, 2022 that was paid in 2021.

 
Appendix

 
Encompass Health 29 Portfolio as of 12/31/21 Inpatient rehabilitation hospitals (“IRFs”) Home health locations Hospice locations 25 Future IRFs** 42 States and Puerto Rico ~43,400 employees Inpatient rehabilitation - 12/31/21 145 IRFs (54 are joint ventures) 35 States and Puerto Rico ~32,500 Employees 24 % of licensed beds† 31 % of Medicare patients served† Key statistics - trailing 4 quarters ~197,600 Inpatient discharges ~$4.0 Billion in revenue * Excluding markets that have home health licensure barriers ** Future IRFs - Previously announced under development as of February 1, 2022 † Based on 2019 and 2020 data Encompass Health a leading provider of inpatient rehabilitation and home-based care 95 of EHC’s IRFs have an EHC home health location within the service area.* Largest owner and operator of IRFs 4th Largest provider of Medicare-certified skilled home health services one of the 2021 FORTUNE® “World’s Most Admired Companies” Home health and hospice - 12/31/21 251 Home health locations 96 Hospice locations 34 States ~10,900 Employees Key statistics - trailing 4 quarters ~200,600 Home health total admissions ~13,100 Hospice admissions ~$1.1 Billion in revenue

 
Encompass Health 30 Inpatient Rehabilitation Facilities Under Development Expected operations date Joint venture? # of New Beds 2022 2023 2024 De novo IRFs: 1 Shiloh, IL Q1 2022 Yes 40 — — 2 St. Augustine, FL Q1 2022 40 — — 3 Libertyville, IL Q1 2022 60 — — 4 Lakeland, FL Q2 2022 50 — — 5 Cape Coral, FL Q2 2022 40 — — 6 Jacksonville, FL Q2 2022 50 — — 7 Moline, IL Q3 2022 Yes 40 — — 8 Naples, FL Q3 2022 50 — — 9 Grand Forks, ND Q3 2022 Yes 40 — — 10 Eau Claire, WI Q4 2022 Yes 36 — — 11 Owasso, OK 2023 Yes — 40 — 12 Clermont, FL 2023 — 50 — 13 Knoxville, TN 2023 Yes — 73 — 14 Bowie, MD 2023 — 60 — 15 Columbus, GA 2023 Yes — 40 — 16 Prosper, TX 2023 — 40 — 17 Strongville, OH 2023 — 40 — 18 Fitchburg, WI 2023 — 40 — 19 Louisville, KY 2023 Yes — 40 — 20 Kissimmee, FL TBD — — 50 21 Fort Mill, SC TBD — — 39 22 Amarillo, TX TBD — — 40 23 Atlanta, GA TBD Yes — — 40 24 Palm Beach Gardens, FL TBD — — 50 25 Lake Worth, FL TBD — — 50 Bed expansions, net* ~100 ~100 ~100 ~546 ~520 ~370 Expansion activity *Net bed expansions in each year may change due to the timing of certain regulatory approvals and/or construction delays. For 2022 and 2023, the currently expected range for bed expansions is 100 to 150. 2021 expansion activity highlights u Opened 8 inpatient rehabilitation hospitals Ÿ 40-bed hospital in San Angelo, TX Ÿ 50-bed hospital in North Tampa, FL Ÿ 50-bed hospital in Cumming, GA Ÿ 40-bed hospital in Greenville, SC Ÿ 40-bed hospital in Shreveport, LA Ÿ 40-bed hospital in Waco, TX Ÿ 40-bed hospital in Pensacola, FL Ÿ 50-bed hospital in Henry County, GA u Added 117 beds to existing hospitals u Announced plans to build 16 inpatient rehabilitation hospitals u Acquired Frontier Home Health & Hospice Ÿ 9 home health and 11 hospice locations Ÿ 3 new states: Alaska, Washington and Montana IRF development projects announced and underway Home Health and Hospice Locations # of Locations December 31, 2020 323 Acquisitions 22 Opening of new locations 3 Merging of locations (1) December 31, 2021 347 25

 
Encompass Health 31 * Overlap markets have an Encompass Health IRF and an Encompass Health home health location within an approximate 30-mile radius, excluding markets that have home health licensure barriers. Overlap markets are open for 12 months before inclusion in the clinical collaboration rate. The Company continues to improve the patient experience and outcomes through integrated care delivery. Inpatient rehabilitation–home health clinical collaboration (all payors) overlap markets* EHC Home Health Non-EHC Home Health Encompass Health IRF discharges to: Overlap Markets* Clinical Collaboration Rate 17.260 u Clinical collaboration objectives: Ÿ Improve patient experience and outcomes Ÿ Reduce total cost of care across a post-acute episode 72 76 81 89 89 95 25.4% 29.5% 34.0% 35.6% 33.2% 31.9% 2016 2017 2018 2019 2020 2021 40,637 42,950 41,858 44,479 51,287 13,800 17,947 21,547 24,560 25,444 57,761 27,017 uThe clinical collaboration rate has decreased primarily due to Medicare Advantage increasing as a percent of the total patient mix and home health staffing constraints in certain overlap markets.

 
Encompass Health 32 Pre-payment claims denials - inpatient rehabilitation segment Impact to Income Statement Period New Denials Collections of Previously Denied Claims Revenue Reserve for New Denials Update of Reserve for Prior Denials (In Millions) Q4 2021 $1.4 $(8.1) $0.4 $— Q3 2021 (0.5) (9.7) — — Q2 2021 0.1 (6.3) — — Q1 2021 (0.2) (5.2) — — Q4 2020 (0.4) (7.2) — 4.5 Q3 2020 (0.6) (6.3) — — Q2 2020 (1.5) (3.5) — — Q1 2020 4.2 (5.0) 1.3 — Q4 2019 3.8 (4.6) 1.1 — Q3 2019 11.3 (6.1) 3.4 — Q2 2019 3.5 (1.7) 1.1 — Q1 2019 1.6 (2.5) 0.5 — Impact to Balance Sheet Dec. 31, 2021 Dec. 31, 2020 Dec. 31, 2019 (In Millions) Pre-payment claims denials $ 69.0 $ 122.8 $ 155.3 Recorded reserves (25.7) (41.3) (46.6) Net accounts receivable from pre-payment claims denials $ 43.3 $ 81.5 $ 108.7 Background • For several years prior to 2018, under programs designated as “widespread probes,” certain Medicare Administrative Contractors (“MACs”) conducted pre-payment claim reviews and denied payment for certain diagnosis codes. • Since 2018, CMS has replaced the “widespread probes” with the Targeted Probe and Educate (“TPE”) initiative.* • Encompass Health appeals most denials. – MACs identify medical documentation issues as a leading basis for denials. – Encompass Health’s investment in clinical information systems and its medical services department has further improved its documentation and reduced technical denials. • By statute, ALJ decisions are due within 90 days of a request for hearing, but appeals are taking years. HHS has implemented rule changes to address the backlog of appeals, but their effect is uncertain. • In November 2018, a federal court ordered HHS to reduce the backlog in the following increments: a 19% reduction by the end of FY 2019; a 49% reduction by the end of FY 2020; a 75% reduction by the end of FY 2021; and elimination of the backlog by the end of FY 2022. • After years of delay in processing appeals, ALJs recently increased the frequency of hearings and the number of claims set at each hearing. Notwithstanding the recent acceleration, Encompass Health still has ~4,000 claims in the backlog. • Effective March 2020, CMS suspended most Medicare fee-for- service medical reviews during the public health emergency, including TPE and current post-payment reviews, allowing reviews for potential fraud. CMS authorized its contractors to resume reviews as of August 2020. Encompass Health reserves pre-payment claim denials as a reduction of net operating revenues upon notice from a MAC a claim is under review. * For more information regarding TPE, see https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/ Medicare-FFS-Compliance-Programs/Medical-Review/Targeted-Probe-and-EducateTPE.html

 
Encompass Health 33 * This chart does not include ~$387 of finance lease obligations or ~$50 of other notes payable. See the debt schedule on page 34. Debt maturity profile - face value 2021 2022 2023 2024 2024 2025 2026 2027 2028 2029 2030 2031 $350 Senior Notes 5.75% $100 Senior Notes 5.125% ($ in millions) Revolver capacity $239 Term Loans Callable $800 Senior Notes 4.75% $800 Senior Notes 4.5% Revolver As of December 31, 2021*) $762 Available $200 Drawn + $38 reserved for LCs Callable Callable beginning February 2025Callable beginning February 2023 $400 Senior Notes 4.625% Callable beginning April 2026

 
Encompass Health 34 Debt schedule Change in December 31, December 31, Debt vs. ($ in millions) 2021 2020 YE 2020 Advances under $1 billion revolving credit facility, November 2024 - LIBOR +150bps $ 200.0 $ — $ 200.0 Term loan facility, November 2024 - LIBOR +150bps 238.5 251.6 (13.1) Bonds Payable: 5.125% Senior Notes due 2023(2) 99.6 298.1 (198.5) 5.75% Senior Notes due 2025 347.0 346.3 0.7 4.50% Senior Notes due 2028 786.8 785.0 1.8 4.75% Senior Notes due 2030 784.7 783.2 1.5 4.625% Senior Notes due 2031 393.7 393.2 0.5 Other notes payable 49.6 39.8 9.8 Finance lease obligations 386.8 391.7 (4.9) Long-term debt $ 3,286.7 $ 3,288.9 $ (2.2) Debt to Adjusted EBITDA 3.2 x 3.8 x Leverage net of cash on balance sheet 3.1 x 3.6 x Reconciliations to GAAP provided on pages 44-52 Refer to pages 53-54 for end notes.

 
Encompass Health 35 * Includes consolidated inpatient rehabilitation hospitals classified as same store during each period Refer to pages 53-54 for end notes. Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 -10.0 0.0 10.0 20.0 New-store/same-store growth Inpatient Rehabilitation Yuma, AZ (51 beds)(10) Boise, ID (40 beds) Katy, TX (40 beds) North Tampa, FL (50 beds) Cumming, GA (50 beds) Shreveport, LA (40 beds) Waco, TX (40 beds) Greenville, SC (40 beds) Pensacola, FL (40 beds) Henry County, GA (50 beds) Lubbock, TX (40 beds) Discharges Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 New store 1.3% 1.5% 2.4% 2.0% 2.3% 2.1% 1.3% 0.9% 1.0% 1.8% 2.0% 3.6% Same store* (0.2)% 2.2% 3.1% 3.2% 2.4% (12.8)% (2.8)% (3.8)% (2.2)% 16.9% 6.7% 6.0% Total by quarter 1.1% 3.7% 5.5% 5.2% 4.7% (10.7)% (1.5)% (2.9)% (1.2)% 18.7% 8.7% 9.6% Total by year 3.9% (2.6)% 8.7% Same-store year* 1.8% (4.4)% 6.2% Same-store year UDS(11) 1.3% (3.2)% TBD Murrieta, CA (50 beds) Sioux Falls, SD (40 beds) Coralville, IA (40 beds) Beginning in mid-March 2020, volume growth was impacted by COVID-19. Toledo, OH (40 beds) San Angelo, TX (40 beds)

 
Encompass Health 36 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 -20.0 -10.0 0.0 10.0 20.0 30.0 New-store/same-store growth Home Health Total admissions Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 New store 5.7% 2.5% 13.7% 12.6% 13.1% 10.0% 1.1% 1.3% 0.1% 0.9% 1.8% 2.3% Same store* 6.8% 9.3% 10.2% 6.5% 1.2% (14.1)% (6.8)% (5.3)% (3.8)% 13.8% (2.7)% 2.4% Total by quarter 12.4% 11.9% 23.9% 19.0% 14.3% (4.0)% (5.7)% (4.0)% (3.7)% 14.7% (0.9)% 4.7% Total by year 16.9% (0.1)% 3.3% Same-store year* 8.1% (5.9)% 1.9% u In 2019, the Company acquired or opened 27 home health locations. u In 2020, the Company acquired or opened two home health locations and consolidated one former equity method location(3). u In 2021, the Company acquired 11 home health locations, merged one location and consolidated one former equity method location(1). Acquired Frontier Home Health & Hospice (9 home health locations in 5 states) in June 2021 Acquired Alacare Home Health & Hospice (23 home health locations in Alabama) in July 2019 * Includes consolidated home health agencies classified as same-store during each period Refer to pages 53-54 for end notes. Beginning in mid-March 2020, volume growth was impacted by COVID-19.

 
Encompass Health 37 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 -10.0 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 * Includes consolidated hospice agencies classified as same-store during each period New-store/same-store growth Hospice Admissions Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 New store 35.5% 15.7% 34.6% 31.1% 30.9% 30.6% 0.5% 0.7% 0.1% 5.3% 11.3% 10.8% Same store* 13.7% 13.6% 5.8% 10.1% (5.3)% 6.7% 15.8% 16.1% 11.4% (1.9)% (14.0)% (14.5)% Total by quarter 49.2% 29.3% 40.4% 41.2% 25.6% 37.3% 16.3% 16.8% 11.5% 3.4% (2.7)% (3.7)% Total by year 39.8% 23.2% 1.8% Same-store year* 12.2% 8.1% (5.3)% u In 2019, the Company acquired or opened 25 hospice locations. u In 2020, the Company opened one hospice location. u In 2021, the Company acquired or opened 14 hospice locations. Acquired Frontier Home Health & Hospice (11 hospice locations in 5 states) in June 2021 Acquired Alacare Home Health & Hospice (23 hospice locations in Alabama) in July 2019

 
Encompass Health 38 Payment sources (percent of revenues) Inpatient Rehabilitation Segment Home Health and Hospice Segment Consolidated Q4 Q4 Q4 Full Year 2021 2020 2021 2020 2021 2020 2021 2020 Medicare 64.7 % 68.3 % 81.0 % 84.3 % 68.1 % 72.0 % 68.2 % 70.5 % Medicare Advantage 14.0 % 13.6 % 11.2 % 9.9 % 13.4 % 12.7 % 14.2 % 14.2 % Managed care 12.9 % 10.4 % 6.3 % 4.2 % 11.5 % 9.0 % 10.7 % 9.0 % Medicaid 3.9 % 3.9 % 1.4 % 1.4 % 3.4 % 3.3 % 3.5 % 3.4 % Other third-party payors 1.2 % 1.3 % — % — % 0.9 % 1.0 % 0.9 % 0.9 % Workers’ compensation 0.6 % 0.6 % — % 0.1 % 0.5 % 0.5 % 0.5 % 0.5 % Patients 0.5 % 0.5 % 0.1 % — % 0.4 % 0.4 % 0.4 % 0.4 % Other income 2.2 % 1.4 % — % 0.1 % 1.8 % 1.1 % 1.6 % 1.1 % Total 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % 100.0 %

 
Encompass Health 39 Inpatient rehabilitation operational metrics Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2021 2021 2021 2021 2020 2020 2020 2020 2021 2020 ($ in millions) Net patient revenue- inpatient $ 1,015.2 $ 983.7 $ 976.9 $ 942.3 $ 914.9 $ 883.2 $ 808.0 $ 890.0 $ 3,918.1 $ 3,496.1 Net patient revenue- outpatient and other revenues 27.4 27.2 24.7 17.6 18.2 16.2 16.5 19.2 96.9 70.1 Net operating revenues $ 1,042.6 $ 1,010.9 $ 1,001.6 $ 959.9 $ 933.1 $ 899.4 $ 824.5 $ 909.2 $ 4,015.0 $ 3,566.2 (actual amounts) Discharges(12) 50,977 49,983 49,492 47,187 46,503 45,962 41,682 47,750 197,639 181,897 Net patient revenue per discharge $ 19,915 $ 19,681 $ 19,739 $ 19,969 $ 19,674 $ 19,216 $ 19,385 $ 18,639 $ 19,825 $ 19,220 Outpatient visits 37,952 38,904 44,020 40,194 48,786 51,968 15,760 69,743 161,070 186,257 Average length of stay 12.8 12.8 12.7 13.0 12.9 13.0 13.2 12.7 12.8 12.9 Occupancy % 71.5 % 70.6 % 71.1 % 71.4 % 68.7 % 68.8 % 64.5 % 71.3 % 70.0 % 67.7 % # of licensed beds 9,924 9,846 9,701 9,560 9,505 9,437 9,401 9,322 9,924 9,505 Occupied beds 7,096 6,951 6,897 6,826 6,530 6,493 6,064 6,647 6,947 6,435 Full-time equivalents (FTEs)(13) 23,364 23,054 22,535 22,383 22,383 22,147 20,809 22,318 22,834 21,915 Contract labor 516 383 318 221 192 176 116 161 359 161 Total FTE and contract labor 23,880 23,437 22,853 22,604 22,575 22,323 20,925 22,479 23,193 22,076 EPOB(14) 3.37 3.37 3.31 3.31 3.46 3.44 3.45 3.38 3.34 3.43 Refer to pages 53-54 for end notes.

 
Encompass Health 40 Home health and hospice operational metrics Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2021 2021 2021 2021 2020 2020 2020 2020 2021 2020 ($ in millions) Net home health revenue $ 224.0 $ 221.1 $ 232.3 $ 219.9 $ 227.7 $ 223.3 $ 201.8 $ 224.8 $ 897.3 $ 877.6 Net hospice revenue 52.1 52.8 53.8 50.6 53.6 51.2 47.8 48.0 209.3 200.6 Net operating revenues $ 276.1 $ 273.9 $ 286.1 $ 270.5 $ 281.3 $ 274.5 $ 249.6 $ 272.8 $ 1,106.6 $ 1,078.2 Home Health: (actual amounts) Total admissions(15) 50,817 48,412 50,598 50,799 48,533 48,838 44,124 52,754 200,626 194,249 Episodic admissions(15) 37,908 37,577 39,657 40,215 40,830 40,765 34,841 42,476 155,357 158,912 Total recertifications 32,621 32,942 33,794 31,902 33,497 33,786 31,952 29,463 131,259 128,698 Episodic recertifications 27,273 27,742 28,296 28,083 30,064 29,830 28,328 26,553 111,394 114,775 Episodes 64,242 66,065 67,839 66,435 71,441 68,261 60,154 68,652 264,581 268,508 Average revenue per episode $ 3,010 $ 2,916 $ 2,968 $ 2,923 $ 2,883 $ 2,910 $ 2,920 $ 2,909 $ 2,954 $ 2,905 Episodic visits per episode 15.1 15.0 15.6 15.8 15.7 16.4 17.4 16.3 15.4 16.4 Total visits 1,219,906 1,213,370 1,297,350 1,239,073 1,281,830 1,300,866 1,250,546 1,306,230 4,969,699 5,139,472 Cost per visit $ 83 $ 82 $ 76 $ 77 $ 76 $ 75 $ 89 $ 81 $ 79 $ 80 Hospice: Admissions(16) 3,223 3,262 3,298 3,330 3,348 3,354 3,190 2,986 13,113 12,878 Patient days 334,011 352,691 351,878 334,400 349,989 346,019 336,507 334,545 1,372,980 1,367,060 Average daily census 3,631 3,834 3,867 3,716 3,804 3,761 3,698 3,676 3,762 $ 3,735 Revenue per day $ 156 $ 150 $ 153 $ 151 $ 153 $ 148 $ 142 $ 144 $ 152 $ 147 Refer to pages 53-54 for end notes.

 
Encompass Health 41 Share information Weighted Average for the Period Q4 Full Year (in millions) 2021 2020 2021 2020 2019 Basic shares outstanding 99.0 98.7 99.0 98.6 98.0 Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants 1.2 1.4 1.2 1.2 1.4 Diluted shares outstanding 100.2 100.1 100.2 99.8 99.4 End of Period Q4 Full Year (in millions) 2021 2020 2021 2020 2019 Basic shares outstanding 99.5 99.4 99.5 99.4 98.6

 
Encompass Health 42 Segment operating results Q4 2021 Q4 2020 ($ in millions) IRF Home Health and Hospice Reclasses Consolidated IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 1,042.6 $ 276.1 $ — $ 1,318.7 $ 933.1 $ 281.3 $ — $ 1,214.4 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (572.4) — (188.6) (761.0) (495.1) — (191.0) (686.1) Other operating expenses(a) (151.1) — (22.9) (174.0) (140.2) — (21.9) (162.1) Supplies (48.1) — (6.1) (54.2) (44.1) — (7.6) (51.7) Occupancy costs (14.5) — (5.5) (20.0) (15.4) — (5.0) (20.4) Home Health and Hospice: Cost of services (excluding depreciation and amortization) — (124.6) 124.6 — — (121.9) 121.9 — Support and overhead costs — (98.5) 98.5 — — (103.6) 103.6 — (786.1) (223.1) — (1,009.2) (694.8) (225.5) — (920.3) Other income(b)(c) 2.4 — — 2.4 4.1 — — 4.1 Equity in net income of nonconsolidated affiliates 1.0 0.1 — 1.1 0.9 0.1 — 1.0 Noncontrolling interests (23.6) (0.5) — (24.1) (25.3) (0.4) — (25.7) Segment Adjusted EBITDA $ 236.3 $ 52.6 $ — 288.9 $ 218.0 $ 55.5 $ — 273.5 General and administrative expenses(d)(e) (36.2) (33.6) Adjusted EBITDA $ 252.7 $ 239.9 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal or impairment of assets $ 2.9 $ (0.1) $ — $ 2.8 $ 1.0 $ — $ — $ 1.0 (b) Change in fair market value of equity securities $ (0.3) $ — $ — $ (0.3) $ (0.1) $ — $ — $ (0.1) (c) Gain on consolidation of former equity method location(1) $ — $ (3.2) $ — $ (3.2) $ — $ — $ — $ — (d) Stock-based compensation $ — $ — $ — $ 11.1 $ — $ — $ — $ 4.2 (e) Costs associated with the strategic alternatives review $ — $ — $ — $ 13.3 $ — $ — $ — $ — Reconciliations to GAAP provided on pages 44-52 Refer to pages 53-54 for end notes.

 
Encompass Health 43 Segment operating results Year Ended December 31, 2021 Year Ended December 31, 2020 ($ in millions) IRF Home Health and Hospice Reclasses Consolidated IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 4,015.0 $ 1,106.6 $ — $ 5,121.6 $ 3,566.2 $ 1,078.2 $ — $ 4,644.4 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (2,127.3) — (759.2) (2,886.5) (1,903.8) — (776.7) (2,680.5) Other operating expenses(a) (594.8) — (90.0) (684.8) (534.7) — (88.1) (622.8) Supplies (184.2) — (25.1) (209.3) (171.0) — (29.5) (200.5) Occupancy costs (59.0) — (21.2) (80.2) (61.4) — (19.8) (81.2) Home Health and Hospice: Cost of services (excluding depreciation and amortization) — (489.3) 489.3 — — (511.3) 511.3 — Support and overhead costs(b) — (406.2) 406.2 — — (402.8) 402.8 — (2,965.3) (895.5) — (3,860.8) (2,670.9) (914.1) — (3,585.0) Other income(c)(d) 6.9 1.6 — 8.5 8.0 — — 8.0 Equity in net income of nonconsolidated affiliates 3.4 0.6 — 4.0 3.0 0.5 — 3.5 Noncontrolling interests (103.2) (1.8) — (105.0) (83.3) (1.3) — (84.6) Segment Adjusted EBITDA $ 956.8 $ 211.5 $ — 1,168.3 $ 823.0 $ 163.3 $ — 986.3 General and administrative expenses(e)(f)(g) (140.3) (126.0) Adjusted EBITDA $ 1,028.0 $ 860.3 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal or impairment of assets $ 1.2 $ (0.8) $ — $ 0.4 $ 10.4 $ 1.2 $ — $ 11.6 (b) Payroll taxes on SARs exercise(5) $ — $ — $ — $ — $ — $ 1.5 $ — $ 1.5 (c) Change in fair market value of equity securities $ (0.6) $ — $ — $ (0.6) $ (0.4) $ — $ — $ (0.4) (d) Gain on consolidation of former equity method location(1)(3) $ — $ (3.2) $ — $ (3.2) $ — $ (2.2) $ — $ (2.2) (e) Stock-based compensation $ — $ — $ — $ 32.8 $ — $ — $ — $ 29.5 (f) Costs associated with the strategic alternatives review $ — $ — $ — $ 22.9 $ — $ — $ — $ — (g) Costs associated with the Frontier acquisition $ — $ — $ — $ 1.3 $ — $ — $ — $ — Reconciliations to GAAP provided on pages 44-52 Refer to pages 53-54 for end notes.

 
Encompass Health 44 Reconciliation of net income to Adjusted EBITDA(8) 2021 Q1 Q2 Q3 Q4 Full Year ($ in millions, except per share data) Total Per Share Total Per Share Total Per Share Total Per Share Total Per Share Net Income $ 132.8 $ 142.0 $ 126.7 $ 115.7 $ 517.2 Loss from disc ops, net of tax, attributable to Encompass Health — 0.3 0.1 — 0.4 Net income attributable to noncontrolling interests (25.5) (28.7) (26.7) (24.1) (105.0) Income from continuing operations attributable to Encompass Health* 107.3 $ 1.07 113.6 $ 1.13 100.1 $ 1.00 91.6 $ 0.91 412.6 $ 4.11 Provision for income tax expense 34.5 39.5 34.1 31.5 139.6 Interest expense and amortization of debt discounts and fees 42.8 41.8 39.9 40.1 164.6 Depreciation and amortization 62.5 63.4 64.9 65.8 256.6 Loss on early extinguishment of debt(2) — 1.0 — — 1.0 (Gain) loss on disposal or impairment of assets (0.1) 2.9 (5.2) 2.8 0.4 Stock-based compensation 2.8 12.0 6.9 11.1 32.8 Costs associated with the strategic alternatives review 0.9 4.1 4.6 13.3 22.9 Costs associated with the Frontier acquisition — 1.3 — — 1.3 Gain on consolidation of former equity method location(1) — — — (3.2) (3.2) Change in fair market value of equity securities 0.1 (0.7) 0.3 (0.3) (0.6) Adjusted EBITDA $ 250.8 $ 278.9 $ 245.6 $ 252.7 $ 1,028.0 Weighted average common shares outstanding: Basic 99.0 99.0 99.0 99.0 99.0 Diluted 100.2 100.2 100.2 100.2 100.2 * Per share amounts for each period presented are based on diluted weighted-average shares outstanding. Refer to pages 53-54 for end notes.

 
Encompass Health 45 Reconciliation of net income to Adjusted EBITDA(8) 2020 Q1 Q2 Q3 Q4 Full Year ($ in millions, except per share data) Total Per Share Total Per Share Total Per Share Total Per Share Total Per Share Net Income $ 108.7 $ 48.3 $ 100.1 $ 111.7 $ 368.8 Loss (income) from disc ops, net of tax, attributable to Encompass Health 0.1 (0.1) — — — Net income attributable to noncontrolling interests (21.7) (14.8) (22.4) (25.7) (84.6) Income from continuing operations attributable to Encompass Health* 87.1 $ 0.87 33.4 $ 0.34 77.7 $ 0.78 86.0 $ 0.86 284.2 $ 2.85 Government, class action, and related settlements 2.8 — — — 2.8 Provision for income tax expense 27.1 11.8 26.9 38.0 103.8 Interest expense and amortization of debt discounts and fees 43.2 45.8 49.0 46.2 184.2 Depreciation and amortization 58.8 60.7 61.2 62.3 243.0 Loss on early extinguishment of debt(17) — — — 2.3 2.3 Loss on disposal or impairment of assets 0.1 3.0 7.5 1.0 11.6 Stock-based compensation 7.1 9.9 8.3 4.2 29.5 Gain on consolidation of former equity method location(3) (2.2) — — — (2.2) Change in fair market value of equity securities 2.5 (2.4) (0.4) (0.1) (0.4) Payroll taxes on SARs exercise(5) 1.5 — — — 1.5 Adjusted EBITDA $ 228.0 $ 162.2 $ 230.2 $ 239.9 $ 860.3 Weighted average common shares outstanding: Basic 98.2 98.7 98.7 98.7 98.6 Diluted 99.6 99.9 99.9 100.1 99.8 * Per share amounts for each period presented are based on diluted weighted-average shares outstanding. Refer to pages 53-54 for end notes.

 
Encompass Health 46 Net cash provided by operating activities reconciled to Adjusted EBITDA(8) Q4 Full Year ($ in millions) 2021 2020 2021 2020 Net cash provided by operating activities $ 123.8 $ 279.7 $ 715.8 $ 704.7 Interest expense and amortization of debt discounts and fees 40.1 46.2 164.6 184.2 Equity in net income of nonconsolidated affiliates 1.1 1.0 4.0 3.5 Net income attributable to noncontrolling interests in continuing operations (24.1) (25.7) (105.0) (84.6) Amortization of debt-related items (2.0) (2.1) (7.8) (7.2) Distributions from nonconsolidated affiliates (0.2) (1.0) (2.9) (3.8) Current portion of income tax expense (benefit) 8.1 (20.1) 111.8 51.4 Change in assets and liabilities 91.0 (40.4) 118.0 7.3 Cash used in operating activities of discontinued operations (0.1) — 0.5 0.2 Costs associated with the strategic alternatives review 13.3 — 22.9 — Costs associated with the Frontier acquisition — — 1.3 — Payroll taxes on SARs exercise(5) — — — 1.5 Change in fair market value of equity securities (0.3) (0.1) (0.6) (0.4) Other 2.0 2.4 5.4 3.5 Adjusted EBITDA $ 252.7 $ 239.9 $ 1,028.0 $ 860.3 Refer to pages 53-54 for end notes.

 
Encompass Health 47 Reconciliation of segment Adjusted EBITDA to income from continuing operations before income tax expense Three Months Ended Year Ended December 31, December 31, 2021 2020 2021 2020 ($ in millions) Total segment Adjusted EBITDA $ 288.9 $ 273.5 $ 1,168.3 $ 986.3 General and administrative expenses (60.6) (37.8) (197.3) (155.5) Depreciation and amortization (65.8) (62.3) (256.6) (243.0) Loss on disposal or impairment of assets (2.8) (1.0) (0.4) (11.6) Government, class action, and related settlements(4) — — — (2.8) Loss on early extinguishment of debt(2)(17) — (2.3) (1.0) (2.3) Interest expense and amortization of debt discounts and fees (40.1) (46.2) (164.6) (184.2) Net income attributable to noncontrolling interests 24.1 25.7 105.0 84.6 Change in fair market value of equity securities 0.3 0.1 0.6 0.4 Gain on consolidation of former equity method location(1)(3) 3.2 — 3.2 2.2 Payroll taxes on SARs exercise(5) — — — (1.5) Income from continuing operations before income tax expense $ 147.2 $ 149.7 $ 657.2 $ 472.6 Refer to pages 53-54 for end notes.

 
Encompass Health 48 Reconciliation of net cash provided by operating activities to adjusted free cash flow(7) Q4 Full Year ($ in millions) 2021 2020 2021 2020 Net cash provided by operating activities $ 123.8 $ 279.7 $ 715.8 $ 704.7 Impact of discontinued operations (0.1) — 0.5 0.2 Net cash provided by operating activities of continuing operations 123.7 279.7 716.3 704.9 Capital expenditures for maintenance (52.9) (47.4) (138.8) (154.9) Distributions paid to noncontrolling interests of consolidated affiliates (25.1) (19.3) (102.9) (72.2) Items not indicative of ongoing operating performance: Cash paid for SARs exercise (inclusive of payroll taxes)(5) — — — 102.1 Transaction costs and related assumed liabilities 16.0 — 24.2 — Adjusted free cash flow $ 61.7 $ 213.0 $ 498.8 $ 579.9 Cash dividends on common stock $ 27.7 $ 27.6 $ 112.4 $ 111.9 Refer to pages 53-54 for end notes.

 
Encompass Health 49 Adjusted EPS(6) - Q4 2021 For the Three Months Ended December 31, 2021 Adjustments As Reported Income Tax Adjustments Costs Associated with the Strategic Alternatives Review Change in Fair Market Value of Equity Securities Gain on Consolidation of Former Equity Method Location As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 252.7 $ — $ — $ — $ — $ 252.7 Depreciation and amortization (65.8) — — — — (65.8) Interest expense and amortization of debt discounts and fees (40.1) — — — — (40.1) Stock-based compensation (11.1) — — — — (11.1) Loss on disposal or impairment of assets (2.8) — — — — (2.8) Costs associated with the strategic alternatives review (13.3) — 13.3 — — — Change in fair market value of equity securities 0.3 — — (0.3) — — Gain on consolidation of former equity method location(1) 3.2 — — — (3.2) — Income from continuing operations before income tax expense 123.1 — 13.3 (0.3) (3.2) 132.9 Provision for income tax expense (31.5) (1.3) (3.4) 0.1 0.8 (35.3) Income from continuing operations attributable to Encompass Health $ 91.6 $ (1.3) $ 9.9 $ (0.2) $ (2.4) $ 97.6 Diluted earnings per share from continuing operations* $ 0.91 $ (0.01) $ 0.10 $ — $ (0.02) $ 0.97 Diluted shares used in calculation 100.2 * Adjusted EPS may not sum across due to rounding. Refer to pages 53-54 for end notes.

 
Encompass Health 50 For the Three Months Ended December 31, 2020 Adjustments As Reported Loss on Early Exting. of Debt Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 239.9 $ — $ — $ — $ 239.9 Depreciation and amortization (62.3) — — — (62.3) Loss on early extinguishment of debt(17) (2.3) 2.3 — — — Interest expense and amortization of debt discounts and fees (46.2) — — — (46.2) Stock-based compensation (4.2) — — — (4.2) Loss on disposal or impairment of assets (1.0) — — — (1.0) Change in fair market value of equity securities 0.1 — — (0.1) — Income from continuing operations before income tax expense 124.0 2.3 — (0.1) 126.2 Provision for income tax expense (38.0) (0.6) 5.6 — (33.0) Income from continuing operations attributable to Encompass Health $ 86.0 $ 1.7 $ 5.6 $ (0.1) $ 93.2 Diluted earnings per share from continuing operations* $ 0.86 $ 0.02 $ 0.06 $ — $ 0.93 Diluted shares used in calculation 100.1 Adjusted EPS(6) - Q4 2020 * Adjusted EPS may not sum across due to rounding. Refer to pages 53-54 for end notes.

 
Encompass Health 51 For the Year Ended December 31, 2021 Adjustments As Reported Loss on Early Exting. of Debt Income Tax Adjustments Costs Associated with the Strategic Alternatives Review Costs Associated with the Frontier Acquisition Change in Fair Market Value of Equity Securities Gain on Consolidation of Former Equity Method Location(1) As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 1,028.0 $ — $ — $ — $ — $ — $ — $ 1,028.0 Depreciation and amortization (256.6) — — — — — — (256.6) Loss on early extinguishment of debt(2) (1.0) 1.0 — — — — — — Interest expense and amortization of debt discounts and fees (164.6) — — — — — — (164.6) Stock-based compensation (32.8) — — — — — — (32.8) Loss on disposal or impairment of assets (0.4) — — — — — — (0.4) Costs associated with the strategic alternatives review (22.9) — — 22.9 — — — — Costs associated with the Frontier acquisition (1.3) — — — 1.3 — — — Change in fair market value of equity securities 0.6 — — — — (0.6) — — Gain on consolidation of former equity method location(1) 3.2 — — — — — (3.2) — Income from continuing operations before income tax expense $ 552.2 1.0 — 22.9 1.3 (0.6) (3.2) 573.6 Provision for income tax expense (139.6) (0.3) (4.9) (5.9) (0.3) 0.2 0.8 (150.0) Income from continuing operations attributable to Encompass Health $ 412.6 $ 0.7 $ (4.9) $ 17.0 $ 1.0 $ (0.4) $ (2.4) $ 423.6 Diluted earnings per share from continuing operations* $ 4.11 $ 0.01 $ (0.05) $ 0.17 $ 0.01 $ — $ (0.02) $ 4.23 Diluted shares used in calculation 100.2 Adjusted EPS(6) - 2021 * Adjusted EPS may not sum across due to rounding. Refer to pages 53-54 for end notes.

 
Encompass Health 52 For the Year Ended December 31, 2020 Adjustments As Reported Gov't, Class Action, & Related Settlements Loss on Early Exting. of Debt Income Tax Adjustments Change in Fair Market Value of Equity Securities Gain on Consolidation of Former Equity Method Location(3) Payroll Taxes on SARs Exercise As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 860.3 $ — $ — $ — $ — $ — $ — $ 860.3 Depreciation and amortization (243.0) — — — — — — (243.0) Government, class action, and related settlements(4) (2.8) 2.8 — — — — — — Loss on early extinguishment of debt(17) (2.3) — 2.3 — — — — — Interest expense and amortization of debt discounts and fees (184.2) — — — — — — (184.2) Stock-based compensation (29.5) — — — — — — (29.5) Loss on disposal or impairments of assets (11.6) — — — — — — (11.6) Change in fair market value of equity securities 0.4 — — — (0.4) — — — Gain on consolidation of former equity method location(3) 2.2 — — — — (2.2) — — Payroll taxes on SARs exercise(5) (1.5) — — — — — 1.5 — Income from continuing operations before income tax expense 388.0 2.8 2.3 — (0.4) (2.2) 1.5 392.0 Provision for income tax expense (103.8) (0.7) (0.6) 1.0 0.1 0.6 (0.4) (103.8) Income from continuing operations attributable to Encompass Health $ 284.2 $ 2.1 $ 1.7 $ 1.0 $ (0.3) $ (1.6) $ 1.1 $ 288.2 Diluted earnings per share from continuing operations* $ 2.85 $ 0.02 $ 0.02 $ 0.01 $ — $ (0.02) $ 0.01 $ 2.89 Diluted shares used in calculation 99.8 Adjusted EPS(6) - 2020 * Adjusted EPS may not sum across due to rounding. Refer to pages 53-54 for end notes.

 
Encompass Health 53 End notes (1) As a result of an amendment to the joint venture agreement related to our home health location in Boynton Beach, Florida, the accounting for this agency changed from the equity method of accounting to a consolidated entity effective December 1, 2021. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. As a result of our consolidation of this agency and the remeasurement of our previously held equity interest at fair value, we recorded a $3.2 million gain as part of other income in the fourth quarter of 2021. (2) In the second quarter of 2021, the Company redeemed a total of $200 million of 5.125% Senior Notes due 2023 ($100 million in April and $100 million in June). The redemptions were completed at 100% of par using cash on hand and drawings under the Company’s revolving credit facility. As a result of the redemptions, the Company recorded a $1.0 million loss on early extinguishment of debt in the second quarter of 2021. (3) As a result of an amendment to the joint venture agreement related to our home health location in Treasure Coast, Florida, the accounting for this agency changed from the equity method of accounting to a consolidated entity effective January 1, 2020. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. As a result of our consolidation of this agency and the remeasurement of our previously held equity interest at fair value, we recorded a $2.2 million gain as part of other income in the first quarter of 2020. (4) As previously disclosed, from 2013 to 2019, the Company cooperated with an investigation of alleged improper or fraudulent Medicare and Medicaid claims. The investigation, under the direction of DOJ, produced no evidence of fraud, falsity or wrongdoing. However, based on discussions with DOJ, and having considered the burdens and distractions associated with continuing the investigation and the likely costs of future litigation, the Company estimated a settlement value of $48 million and accrued a loss contingency in that amount in the fourth quarter of 2018. Following further discussions, the Company entered into an agreement effective as of June 21, 2019 to settle all claims related to the DOJ investigation, together with related qui tam or “whistleblower” lawsuits, for cash payments totaling $48 million. (5) In connection with the 2014 acquisition of Encompass Home Health and Hospice, the Company granted stock appreciation rights (“SARs”) based on the fair value of the common stock of Home Health Holdings to certain members of that management team. Half of the SARs vested on Jan. 1, 2019, and the other half vested on Jan. 1, 2020. The fair value of the SARs was determined using the product of Home Health Holdings’ EBITDA for the trailing 12-month period and a median market price multiple based on a basket of public home health companies and recent transactions, less the current balance of any intracompany note to the parent. In Q1 2019 and Q3 2019, holders exercised vested SARs for cash proceeds of approximately $13 million and approximately $55 million, respectively. In Q1 2020, holders exercised the remaining SARs for cash proceeds of approximately $101 million. (6) The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”), which is a non- GAAP measure. The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements, professional fees - accounting, tax, and legal, mark-to-market adjustments for stock appreciation rights, gains or losses related to hedging and equity instruments, loss on early extinguishment of debt, adjustments to its income tax provision (such as valuation allowance adjustments, settlements of income tax claims and windfall tax benefits), items related to corporate and facility restructurings, and certain other items deemed to be non-indicative of ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company's ongoing operating performance. Accordingly, they can complicate comparisons of the Company's results of operations across periods and comparisons of the Company's results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies.* (7) Definition of adjusted free cash flow, which is a non-GAAP measure, is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, dividends paid on preferred stock, distributions to noncontrolling interests, and certain other items deemed to be non-indicative of ongoing operating performance. Common stock dividends are not included in the calculation of adjusted free cash flow. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. (8) Adjusted EBITDA is a non-GAAP financial measure. The Company’s leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future the Company may incur expenses similar to the adjustments set forth. * Reconciliations to GAAP provided on pages 44-52.

 
Encompass Health 54 End notes, continued (9) On Oct. 28, 2013, the Company announced its board of directors authorized the repurchase of up to $200 million of its common stock. On Feb. 14, 2014, the Company's board approved an increase in this common stock repurchase authorization from $200 million to $250 million. As of June 30, 2018, the remaining repurchase authorization was approximately $58 million. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $250 million. As of December 31, 2021, the remaining repurchase authorization was approximately $198 million. (10) As a result of negotiations with our partner to amend the joint venture agreement related to Yuma Rehabilitation Hospital, the accounting for this hospital changed from the equity method of accounting to a consolidated entity effective July 1, 2019. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, we recorded a $19.2 million gain as part of other income in the third quarter of 2019. (11) Data provided by Uniform Data System for Medical Rehabilitation, a division of UB Foundation Activities, Inc., a data gathering and analysis organization for the rehabilitation industry; represents ~80% of industry, including Encompass Health inpatient rehabilitation sites (12) Represents discharges from 145 consolidated hospitals in Q4 2021; 144 consolidated hospitals in Q3 2021; 140 consolidated hospitals in Q2 2021; 138 consolidated hospitals in Q1 2021; 137 consolidated hospitals in Q4 2020; 136 consolidated hospitals in Q3 and Q2 2020; and 134 consolidated hospitals in Q1 2020. (13) Full-time equivalents included in the table represent Encompass Health employees who participate in or support the operations of our hospitals and include an estimate of full-time equivalents related to contract labor. (14) Employees per occupied bed, or “EPOB,” is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company’s occupancy percentage. (15) Represents home health admissions from 251 consolidated locations in Q4 2021; 248 consolidated locations in Q3 2021 and Q2 2021; 240 consolidated locations in Q1 2021 and Q4 2020; 241 consolidated locations in Q3 2020; 244 consolidated locations in Q2 and Q1 2020. (16) Represents hospice admissions from 96 locations in Q4 2021; 95 locations in Q3 2021; 94 locations in Q2 2021; 82 locations in Q1 2021 and Q4 2020; 83 locations in Q3, Q2 and Q1 2020. (17) In October 2020, the Company issued $400 million of 4.625% Senior Notes due 2031. The proceeds plus approximately $300 million of cash on hand were used to fully redeem $700 million of 5.75% Senior Notes due 2024 at par on November 1, 2020. As a result of this redemption, the Company recorded an approximate $2 million loss on early extinguishment of debt in the fourth quarter of 2020.